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ABSTRACT
A Novel Correction for the Adjusted Box-Pierce Test — New Risk Factors for Emergency
Department Return Visits within 72 hours for Children with Respiratory Conditions —
General Pediatric Model for Understanding and Predicting Prolonged Length of Stay
by Sidy Danioko

This thesis represents the results of three research projects that underline the breadth and
depth of my interests.
Firstly, I devoted some efforts to the well-known Box-Pierce goodness-of-fit tests for time
series models which has been an important research topic over the last few decades. All
previously proposed tests are focused on changes of the test statistics. Instead, I adopted a
different approach that takes the best performing test and modifying the rejection region.
Thus, I developed a semiparametric correction of the Adjusted Box-Pierce test that attains
the best I error rates for all sample sizes and lags and outperforms all previous global time
series goodness-of-fit approaches.
Secondly, I aimed to study and identify novel risk factors significantly associated with 72hour return visits to emergency departments. We queried data consisting of 185,000 ED
visits of patients less than 18 years in the United States using the Cerner® Health Facts
Database. A nested mixed-effects logistic regression model to provide statistical inference
on associated risk factors was built, and a representative set of machine learning algorithms
for our predictive modeling task was selected. New respiratory conditions including acute
bronchiolitis, pneumonia, and asthma were identified as risk factors for return visits to ED.
Thirdly, I ambitioned to design and implement a comprehensive study to identify new clinical
and demographic factors associated with prolonged length of stay (> two weeks) among
pediatric patients (aged 18 years and under) in a number of free-standing pediatric and mixed

VI

medical facilities. We implemented a mixed effect model to assess the statistical significance
and effect sizes of age, race/ethnicity, number of medications, medical family history, presence
of infection agents (fungi, bacteria, virus), cancer diagnoses, and other conditions as well as
some clinical variables. A stochastic gradient model was also implemented for prediction.
From the mixed-effects model, 11 main effect predictors were found to be significantly and
statistically associated with an increase in the odds of prolonged length of stay. The area
under the operator characteristic curve (AUROC) for the mixed-effects model was 0.887
(0.885, 0.889) and the extreme gradient boosting model attained an AUROC of 0.931 (0.930,
0.933).
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1

Introduction

Currently, data accumulation is accelerating and touching every domain of life. For example,
in physics time series arises quite often when studying very dynamic complex systems. In
engineering, electricians are always engaged in better understanding the time dependent aspects of power flow over a fixed interval of time. In medicine, doctors daily or weekly conduct
lab tests or other screening techniques on patients. In social sciences, the population growth
rates are regularly measured in the hope of prescribing trends and design recommendations
for the future. In finance and economics, the daily, weekly, and monthly prices of stocks are
constantly collected for studies leading to better investment plans. In the industry world,
some scientists observe the time evolution of the densities of plasma.
Data come in many forms including structured, unstructured, semi-structured, discrete,
continuous, high dimensional, to just name a few. Due to the existence of various types of
data and the multitude of research questions that can be posed, understanding and modeling
have been attracting various communities of researchers and practitioners. Particularly
important has been the presence of the notion of data and the science behind data (data
science) at the intersection of all the above-cited data related activities. Arguably, data
science has been viewed as a study domain that lies at the intersection of math and statistical
knowledge, hacking skills, and very broad and deep expertise. From all the difficulties of
generating a considerable amount of data to a world submerged by data, the field of data
science has evolved in several directions and matured in numerous aspects. With time and the
abundance of data (structured and unstructured), data science has gradually become one of
the intellectually stimulating research areas within companies, universities, and governments.
In fact, finding sound mathematical theory and computational algorithms have produced
unprecedented success stories. Nevertheless, uncountable practical applications and active
research topics continue to emerge. Thus, it is still acceptable to say that data science has

1

not yet reached a completely mature stage.
I have devoted parts of my doctoral work to both extending theoretical results and investigating medical data in the hope of gaining understanding, insight, and knowledge with
respect to situations that are inflecting serious psychological and financial burdens on patients and hospitals as well. This dissertation consists of four parts. Part I is devoted to
the introduction. Part II is focused to creating a novel correction to the adjusted version
of the Ljung-Box statistic, one of the most popular time series goodness-of-fit diagnostic
test statistics. Part III addresses the risk factors of 72-hour return visits attributable to
the most common respiratory conditions and the contribution of non-respiratory comorbid
conditions/diseases. Part IV is concerned with designing and implementing a comprehensive
study to identify new clinical and demographic factors associated with prolonged length of
stay (> two weeks) among pediatric patients (aged 18 years and under) in a number of
free-standing pediatric and mixed medical facilities.

2

2

A Novel Correction for the Adjusted
Box-Pierce Test

The Box-Jenkins algorithm is a general systematic approach for model checking of a time series model. Examples of the approach can be found in [1], [2] and , [3]. A well-fitting model
produces residuals that are free of correlation. Thus standard goodness-of-fit approaches are
in essence global tests for absence of correlation among estimated residuals. Accordingly,
many statistical techniques have been designed to assess the absence of correlation among
the time series model residuals.
Following classical notation, let {Xt } be an observed time series generated by a stationary and
invertible ARMA(p,q) process φ(B)Xt = θ(B)t , where φ(B) and θ(B) are the autoregressive
and moving average characteristic polynomial and Bk Xt = Xt−k is the backshift operator.
The desired parameters, φi and θi are estimated using maximum likelihood or least squares
methods to obtain φ̂i and θ̂i , the residuals are calculated via ˆt = θ̂−1 (B)φ̂(B)Xt and the
P
Pn 2
sample auto-correlation coefficients are in turn obtained from r̂k = n
t=k+1 ˆt ˆt−k / t=1 ˆt .
In recent years, many techniques have been employed to test the global hypothesis of all
autocorrelations up to a certain lag, H0 : r1 = r2 = ... = rm = 0. In general, these
techniques are designed as weighted sums of squares of the estimated autocorrelations and
they can produce misleading conclusions due to deviations from the asymptotic limiting
distribution in moderate size samples [4] , [5], [6]. Thus, a new and more robust test is
proposed in this research that attains precise type I error rates for all sample sizes.
The history of portmanteau tests traces its roots back to the Box-Pierce diagnostic test
defined as [6], [7] :

QBP = n

m
X
k=1

3

r̂k2 ,

(2.1)

where n, m, and r̂k represent the sample size, number of lags being tested and the sample auto-correlation of order k of the residuals respectively. The authors showed that the
asymptotic distribution of QBP is approximately χ2 (m-p-q) but considerable deviations for
moderate sample sizes have been observed [7], [8], [9]. That deficiency entails imperfections
of type I error rates and prompted the design of a weighted and improved versions of the
test. In their stimulation studies, Ray and Xiaolou focused on investigating the type I errors
in the χ2m setting [4]. They remarked that Box-Pierce rejects too often because of the fact
that the test statistic is too small.
Ljung and Box were the first ones to propose a design that assigns larger weights to residuals
estimated with more data [7]:

QLB = n(n + 2)

m
X
k=1

m
X
r̂k2
n+2 2
=n
r̂ .
n−k
n−k k

(2.2)

k=1

The Box-Pierce and Ljung-Box tests are asymptotically equivalent. The Ljung-Box test has
been shown to overcorrect in moderate samples [4]. They also realized that Ljung-Box
inflates the test statistic using a variance estimate of the residuals. They further showed
that on moderate sized data, QLB rejects too often because the test statistic is too small.
Li and McLeod refined the QBP test [9] by proposing the following statistic,

m

X
m(m + 1)
m(m + 1)
QLB = QBP +
=
+n
r̂k ,
2n
2n

(2.3)

k=1

This approach only corrects the mean of the Box-Pierce statistic and consequently fails to
properly adjust the type I error rates.
Monti proposed a portmanteau test based on the residual partial autocorrelations [10]. The
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test is defined as,
QM = n(n + 2)

m
X
π̂k2
,
n−k

(2.4)

k=1

Monti showed via simulations that the performance of QM is comparable to that QLB [10].
In addition, he concluded that in certain scenarios, QLB outperfroms QM .
Peña and Rodríguez proposed a test based on a different measure of dependence of the
residual autocorrelations, [11],
D = n(1 − |R̂m |1/m ),

where



r̂1
 1

 r̂1
1

R̃m =  .
..
 ..
.


r̂m r̂m−1


r̂m 

. . . r̂m−1 


.
...
.. 


...
1

(2.5)

...

(2.6)

In their work, the authors showed that under particular conditions, their test greatly outperformed QLB test. Furthermore, they demonstrated that the test had an advantage over the
McLeod and Li’s test regardless of sample size. However, the convergence of the asymptotic
distribution of the test developed by Peña and Rodríguez is very slow [12].
Fisher proposed new weighted versions of the Box-Pierce and Monti’s tests, the Q statistic:
[5],

m
X
m−k+1 2
r̂ ,
Q̃W L = n(n + 2)
m(n − k) k

(2.7)

m
X
m−k+1 2
Q̃W M = n(n + 2)
π̂ ,
m(n − k) k

(2.8)

k=1

and

k=1

5

A comparison simulation study by [13] showed that for small sample size and m values QW L
performs better than QLB . For moderate sample sized data, they also found that QW L does
better than QLB and QW M outperforms QM .

To remedy some of the shortcomings of all previously existing tests, Kan and Wang proposed
a new modification of the portmanteau test, widely called the adjusted Box-Pierce test [4].
They defined their statistic as,
s
QaBP = m +

2m
(Q
− E[QBP ]),
V ar[QBP ] BP

(2.9)

The authors conducted an evaluation of various tests including Box-Pierce and Ljung-Box.
The design of the adjusted Box-Pierce statistic (2.9) explicitly recenters and rescales QBP to
attain the mean and variance of a χ2 (m) variable. The authors showed through simulations
that the test possesses very good adherence to nominal type I error rates. In their comparison
study, they found that both the distributions of QBP and QLB deviate from the expected
variance of χ2 (m) distribution for small and moderate sample sizes and almost all choices
for the value of m.
All of the above-mentioned tests exhibit deviations from the nominal type I error rates that
compromise their performance. Thus, a new approach is proposed which aims at correcting
the rejection region instead of redesigning the test statistic itself. This technique was introduced by Bernard in his effort to construct a more powerful alternative to Fisher’s exact
test [14] [15] and later by Boschloo [16]. The same idea of rejection region correction has
been recently employed by Ehwerhemuepha et al to produce the best performing test for
homogeneity for multinational distributions [17].

6

2.1

Methods

A model based correction of the rejection region of the adjusted Box-Pierce test was designed.
A large scale simulation study was then conducted to not only estimate the correction, but
to also assess the performance advantages (defined as adherence to the nominal type I error
rates for all scenarios) of the proposed corrected method.

2.1.1

Simulation Study

For sample size values of n = 40, 50, . . . , 300, we simulated 106 white noise samples, sn1 , sn2 , . . . ,
sn106 ∼ Nn (0, I). These mimic the behavior of residuals of a well-fitting time series model
(under the null). Next, the adjusted Box-Pierce test was applied to every sample and for all
possible lags, m (2 ≤ m ≤ n − 1) and the corresponding p-values, pnm1 , pnm2 , . . . , pnm106
were obtained. For each pair (n, m), the estimated the type I error rate of the adjusted BoxP 6
n,m
Pierce test at alpha level of 0.05 was empirically estimated by Pα=0.05 = 10
i=1 I{pnmi <
0.05}/106 . Thus, for each sample size n, n − 2 empirically estimated type I error rates
n,m

yielding a dataset with three columns, n, m, and Pα=0.05 . Further, these datasets obtained
from all individual sample sizes n were stacked to get an aggregated dataset with number of
P
rows 30
n=4 10n(10n − 2) = 934, 920.

2.1.2

Linear model

The primary idea of this study was to provide a model-based correction to the rejection
region of the adjusted Box-Pierce test in order to attain improved type I error rates for all
sample sizes and lags. We created six linear regression models trained on the simulated data
described in the section above. These six models were trained on different subsets of the data
split into sample size intervals, (0, 50],[51, 70], [71, 90], [91, 120], [121, 200], and [201, 300].

7

The difference in the type I error rate patterns for distinct sample seizes (shown in Figure
1) necessitated the use of separate models to achieve the desired level of fit. These linear
models are complex as they encompass different powers of n, m and their 2-way interactions.
The general formula adopted for the models was,

Y − 0.05 = α1 ns + α2 mp + α3 (ns ∗ mp ) + α4 (n2s ∗ m2p ) + α5 n2s
+ α6

(n3s

∗ m2p ) + α

7

(n3s

∗ m3p ) + α

8

m4p

+ α9

(2.10)

m5p .

Further, within the general form (2.10) an extensive grid search to find the best values of the
power transformation parameters s and p was performed. The type I error rates from the
selected best models are presented in Table 4.2. The rates were calculated using validation
data with sample sizes of nval = 45, 65, 85, 100, 250.

Table 2.1: Performance summary of the correction to the
Adjusted Box-Pierce.

Sample size

s

p

AdjBoxPierce

Corrected version

n = 45

0.2

0.3

0.04868907

0.05001953

n = 65

10.0

1.0

0.05163921

0.05002905

n = 85

7.0

2.0

0.05305157

0.05045904

n = 100

1.3

1.7

0.05447408

0.05020469

n = 160

0.8

0.9

0.05629981

0.04987525

n = 250

1.9

0.8

0.05813593

0.05037286
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Table 2.2: Summary statistics for selected variables in
interval sample size less than 50.

Variable

Estimate

Std.Error

t-value

p-value

ns

0.425295

0.251604

1.690

0.095008 .

mp

-1.353900

0.793110

-1.707

0.091837 .

ns ∗ mp

0.593460

0.396921

1.495

0.138960

n2s ∗ m2p

0.149028

0.056476

2.639

0.010065 *

n2s

-0.183531

0.122355

-1.500

0.137706

n3s ∗ m2p

-0.070355

0.030893

-2.277

0.025539 *

n3s ∗ m3p

0.004419

0.002064

2.141

0.035436 *

m4p

-0.017762

0.004355

-4.079

0.000109 ***

m5p

0.002106

0.000461

4.570

1.83e-05 ***

Table 2.3: Summary statistics for selected variables in
finite sample size between 51 and 70.

Variable

Estimate

Std.Error

t-value

p-value

ns

-2.652e-06

8.296e-07

-3.196

0.00179 **

mp

1.209e-03

2.984e-04

4.053

9.12e-05 ***

ns ∗ mp

-2.283e-07

7.347e-08

-3.108

0.00237 **

n2s ∗ m2p

-2.068e-12

3.852e-13

-5.369

4.07e-07 ***

n2s

4.910e-10

1.869e-10

2.627

0.00977 **

n3s ∗ m2p

4.637e-16

8.877e-17

5.223

7.75e-07 ***

n3s ∗ m3p

-1.167e-18

2.439e-19

-4.784

5.05e-06 ***
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m4p

6.138e-10

2.856e-10

2.150

0.03364 *

m5p

2.552e-12

1.811e-12

1.409

0.16150

Table 2.4: Summary statistics for selected variables in
finite sample size between 71 and 90.

Variable

Estimate

Std.Error

t-value

p-value

ns

3.214e-17

2.901e-17

1.108

0.269585

mp

3.833e-06

1.130e-06

3.392

0.000877 ***

ns ∗ mp

-1.392e-20

3.309e-20

-0.421

0.674609

n2s ∗ m2p

-4.627e-36

6.406e-37

-7.224

2.02e-11 ***

n2s

-6.756e-31

6.616e-31

-1.021

0.308740

n3s ∗ m2p

9.423e-50

1.523e-50

6.189

5.00e-09 ***

n3s ∗ m3p

-1.759e-54

4.077e-55

-4.315

2.80e-05 ***

m4p

2.816e-17

2.774e-18

10.153

< 2e-16 ***

Table 2.5: Summary statistics for selected variables in
finite sample size between 91 and 120.

Variable

Estimate

Std.Error

t-value

p-value

ns

5.169e-06

3.434e-06

1.505

0.133211

mp

1.266e-05

3.809e-06

3.323

0.000994 ***

ns ∗ mp

-1.569e-09

9.362e-09

-0.168

0.867045
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n2s ∗ m2p

-2.021e-13

1.482e-14

-13.641

< 2e-16 ***

n2s

-1.216e-08

7.488e-09

-1.624

0.105408

n3s ∗ m2p

3.782e-16

3.539e-17

10.687

< 2e-16 ***

n3s ∗ m3p

-4.778e-20

4.874e-21

-9.804

<2e-16 ***

m4∗p

3.367e-15

1.792e-16

18.793

< 2e-16 ***

m5p

-4.058e-19

3.561e-20

-11.397

< 2e-16 ***

Table 2.6: Summary statistics for selected variables in
finite sample size between 121 and 200.

Variable

Estimate

Std.Error

t-value

p-value

ns

5.966e-05

2.343e-05

2.546

0.01102 *

mp

8.195e-04

5.830e-05

14.056

< 2e-16 ***

ns ∗ mp

-1.227e-05

1.336e-06

-9.181

< 2e-16 ***

n2s ∗ m2p

-8.989e-09

3.701e-10

-24.290

< 2e-16 ***

n2s

-1.271e-06

3.925e-07

-3.237

0.00124 **

n3s ∗ m2p

1.864e-10

5.775e-12

32.280

< 2e-16 ***

n3s ∗ m3p

-1.079e-12

2.925e-14

-36.873

< 2e-16 ***

m4p

1.233e-09

8.712e-11

14.147

< 2e-16 ***

m5p

6.308e-12

6.042e-13

10.440

< 2e-16 ***
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Table 2.7: Summary statistics for selected variables in
finite sample size between 201 and 300.

2.2

Variable

Estimate

Std.Error

t-value

p-value

ns

1.740e-07

5.213e-08

3.338

0.000868 ***

mp

2.056e-04

5.313e-05

3.870

0.000114 ***

ns ∗ mp

1.206e-08

5.327e-09

2.263

0.023777 *

n2s ∗ m2p

-9.680e-14

6.970e-15

-13.889

< 2e-16 ***

n2s

-1.845e-11

2.884e-12

-6.396

2.22e-10 ***

n3s ∗ m2p

5.841e-18

1.928e-19

30.295

< 2e-16 ***

n3s ∗ m3p

-5.966e-20

2.469e-21

-24.161

< 2e-16 ***

m4p

-4.111e-09

5.612e-10

-7.326

4.14e-13 ***

m5p

1.660e-10

7.322e-12

22.678

< 2e-16 ***

Results

Noticeable differences between the patterns of type I error rates across the analyzed sample
sizes (40 to 300) were discovered. Therefore, sample-size specific models (0-50, 51-70, 71-90,
91-120, 120-200, 201-300) were constructed to capture the exact pattern for that particular
scenario. Table 4.2 displays a condensed form of the comparative study between revised version of Box-Pierce, which to the best of our knowledge is the last version, and the correction
that we have brought into the study. For different time series lengths, the corresponding
s and p values along with the type I error rates for the adjusted Box-Pierce and those of
the corrected version that we designed. It is important to realize that the results from the
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implementation of these models show that in all settings, the proposed regression-based correction provided almost perfect type I error rates. In particular, the adjusted type I error
rates after the correction to the rejection regions were exactly 0.05 with detailed results.
Tables 2.2, 2.3, 2.4, 2.5, 2.6, and 2.7 show detailed summary from the sample-size specific
model fits. These models provide a parametric correction of the type I error rates. Graphical
representation of results from the implementation of these models for several scenarios are
shown in Figure 2.1.
Form left-to-right-up-to-down the fitting curves with appropriately found models in cases
where (n = 50, 70, 90, 120, 300) can be viewed. Empirically, it can be seen that the models
that best fit the specific curve in a given data were found.
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Figure 2.1: Parametric correction to the rejection region
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Figure 2.2: Parametric correction to the rejection region

2.3

Data example

An application of our corrected version of the adjusted Box-Pierce test was performed using
S&P 500 stock data. We provide instances of both false positive and false negative results
obtained by the standard adjusted Box-Pierce test using EQT Corporation stock. This corporation created in 1884 and headquartered in Pittsburg is one of the leading companies
extensively devoted to the exploration and transportation of hydrocarbon (Petroleum, natural gas, natural gas liquid). The average daily price of the EQT Corporation was calculated
by collecting its opening and closing prices over a period over 8 years (2010-2018). For a
window size of 50, numerous false negative and false positive points were found at different
lags. In this case, instead of a critical value we have a critical boundary or curve exists. In
this setting, the same rejection conditions are the same as in the normal case.
In Figure 2.2, instances of a false positive rejection at lag 26 are shown where the adjusted
Box-Pierce test obtains a p-value of 0.0504 but the proposed model correction inflates the
rejection region to start at 0.058. The graph also shows a false negative results with p-value
of 0.046 at lag 47. However, the proposed correction shrinks the rejection region to start at
0.045.
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2.4

Discussion

In this work a new apparoch for correction of adjusted Box-Pierce test recently developed by
Kan and Wang [4]. Conceptually, the rejection region correction idea is similar to the ones
successfully employed in the work of [16] and [17] to counterbalance the conservativeness
of exact homogeneity tests. The provided method combines large scale simulations with
subsequent scenario-specific regression modeling that includes complex interaction terms to
achieve exceptionally good fit that entails nominal type I error rates for all sample sizes
and lags used in the test statistic. The regression models that were constructed depend on
the length of the series (n) and the lag order (m). The exponents (s) and (p) of different
variables present in the models are treated as hyperparameters in order to control the learning
process. To obtain optimal values for those hyperparameters an extensive search through
chosen subset values for (s) and (p) was conducted. The simulation study showed that the
test outperforms all existing competing goodness-of-fit approaches for sample sizes up to
300.
The merit to the novel correction to the adjusted Box-Pierce proposed in this study is that
it allows to find a test with vastly improved type I error rates. This proposed technique of
rejection region correction has direct implication on precise decision making by investors and
financial institutions. The same technique can be easily extended to larger sample sizes.

2.5

Summary

Building models forces us to translate our beliefs into the language of mathematics and/or
computer. More often than not, our believes are erroneous since they are based on assumptions. In this process, we can either make under or over assumptions that could lead
to possible misleading us to wrong models with highly destructive consequences. To avoid
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eventual undesirable situations, it is always wise to check for the adequacy of our constructed
models.
To obtain a dream model, notable mathematical, computational and empirical techniques
have been proposed. Some rely on the graphical representation of the estimated residuals
and other focus on the plot of the residual autocorrelation and partial autocrrelation at
a certain number of lags. However, the first method could be subjective thus deceiving,
and the second method only looks at the magnitude and significance of the autocorrelation
coefficients at the individual but not jointly.
In trying to overcome the underscored weaknesses of the above mentioned diagnostic of
Goodness fit tests, more robust techniques such as Box-Pierce, and Ljung-Box have also
been proposed. Despite their success and mathematical soundness, the classical Box-Pierce
and Ljung-Box tests for auto-correlation of residuals also present serious flaws, such as severe
deviations from nominal type I error rates. As a response, many efforts have been deployed
to address this issue by either revising existing tests or designing new techniques. Among all
the refined versions of Ljung-Box tests, the Adjusted Box-Pierce demonstrated a superiority
by achieving the best results with respect to attaining type I error rates closer to nominal
values. Nevertheless, the Adjusted Box-Pierce seems to reject too much.
In this work, we proposed a further correction to the adjusted Box-Pierce test that possesses
near perfect type I error rates. The approach is based on an inflation of the rejection
region for all sample sizes and lags calculated via a linear model applied to simulated data
that encompasses a large range of data scenarios. Our results show that the new approach
possesses the best type I error rates of all goodness-of-fit time series statistics.
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3

New Risk Factors for Emergency
Department Return Visits within 72
Hours for Children with Respiratory
Conditions

3.1

Introduction

Chronic respiratory diseases constitute a set of conditions that mainly affect the airways
and other parts of the lung. Chronic respiratory diseases have become a complex worldwide epidemiological phenomenon that is highly associated with increased morbidity and
mortality[18], [19], [20]. Comparative information about the disease prevalence, visits and
returns to emergency departments, financial and death rates show that chronic respiratory
diseases have become one of the biggest public health and economic burdens claiming 2.5
million lives and costing $8.1 billion in health care costs in 2019 [21], [22], [23], [24], [25].
Globally, more than one billion people suffer from chronic respiratory diseases and an estimated 4 million die each year [26]. Chronic respiratory infections are reported to be the
leading cause of mortality and morbidity in low- or middle-income countries (LMICs) [21],
[22], [23], [24], [25] and [26]. As a result, respiratory infections have become an increasingly
important part of the global public health efforts and research.
Asthma is another dangerous and prevalent condition with global burden of disability [27],
[28], [29]. The Global Asthma Network (GAN), which aims to reduce the suffering from
asthma by preventing asthma case with focus on low- and middle-income countries (LMICs),
reported that almost 339 million people are affected with Asthma [30]. Annually, asthma
is responsible for the death of 489,000 people [21]. With its high rate of mortality and
morbidity, asthma is ranked among the top 20 causes of years of life lived with disability. In
addition to the death tolls, asthma treatment has high economic burden [31].
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Acute lower respiratory infections (ALRIs) kill approximately four million people every year,
with higher impact on low and middle income countries [32] placing them among the top
three causes of death around the world [30]. For example, in 2015, approximately 2.38 million
people lost their lives because of ALRIs [33]. Recently, considerable amount of efforts has
been deployed to reduce the death tolls of ALRIs, nevertheless their importance remains
underestimated mostly in some regions of the globe [33].
Tuberculosis (TB) has long been viewed as one of the most dreadful preventable infectious
diseases. Tuberculosis infects approximately 2 billion people of whom an estimated 2 million
of people die yearly [34]. According to WHO, the costs of TB treatment and management
represent a disproportionately high burden to patients, their families and communities and
governments. For example, each year, tuberculosis accounted for approximately $21 billion including $9.2 billion for treatment and control activities and $12 billion in additional
economic costs and lost productivity.
Lung cancer is one of the cancers with the highest mortality rate which claims more lives
than any other type of cancers [35]. In 2012, there were 1.8 million new cases and 1.6 million
deaths. In 2015, 1.7 million lives were lost due to lung cancer, representing almost 20% of
all cancer-related deaths in the world [36].
Sadly, a great number of patients with chronic respiratory conditions are newborn babies
and small children. Recent research efforts have reported that chronic respiratory diseases
are the conditions related with the highest death rate among children under five years of age.
Chronic Obstructive Pulmonary Disease (COPD), though being conventionally accepted to
be associated with smoking among quadragenarians or older patients[37] also affects many
children. In some studies, it is reported that COPD could take its roots in childhood by
living with adult smokers in the same household [38]. Further, it has been reported that
there is a strong association between childhood death from COPD and poverty [39].
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Asthma is the most common, but non-communicable chronic disease that not only impacts
the quality of life of children, but also significantly contributes to childhood mortality and
morbidity worldwide [40], [41] with a death rate ranging between 0.0 to 7.0 per 1,000 [24].
On a global scale, 14% of children are affected with asthma and as high as one-third of US
children population [42].
Presently, there is no known cure for asthma. However, the disease can be managed with
adequate prevention and treatment therapy. According to recent Center for Disease Control
(CDC) data, 1 in 13 people have asthma resulting in ∼25 million Americans having the
disease and sadly, children account for ∼8% of the patients. Asthma has been on a steady
increase in the last three decades affecting all ages, gender, and ethnicity. Asthma is the
leading chronic disease in children, and it is more common in boys than in girls. Strikingly, it
is the top reason for school absenteeism among school children. In 2013, ∼13 million missed
school days were attributed to asthma. In 2015 and 2016 CDC data, it was observed that
48% of children ages 18 and under who had the disease reported having at least one asthma
attack in the previous year. Likewise, ∼50% of children under the age of 5 with asthma had
an episode.
The financial implications of asthma are enormous with an annual economic cost in the
worth of $80 billion between 2008 and 2013 [31]. The annual per-person incremental medical
cost of asthma was approximately ∼$3,200 in 2015 [31].
Globally, the prevalence of asthma in children has been on the rise [43], [44]. Burr et
al., between two different studies, outlined an increase of 6.5% in the prevalence [45]. A
similar trend in the prevalence of asthma was reported by Burney and Aberdeen in [46],
[47]. With an increasing prevalence, asthma has progressively become the most frequent
cause of hospitalization among children [48]. In theory, the prevalence of asthma symptoms
is assumed to attain higher levels in developed or high-income countries (HICs), however
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LMICs have recently displayed alarming prevalence rates. Recent studies showed that more
severe childhood asthma cases are seen in LCMIs with over 80% of asthma-related deaths
occur in LMICs [49], [50].
Tuberculosis (TB) is another respiratory infection causing a pronounced increase in morbidity
and mortality in children around the world [51], [52], [53] particularly among those from
geographic locations with high incidence and prevalence of HIV [49], [54]. Due to poor
recording and reporting of childhood TB cases, lack of resources, and limited amount of
pediatric surveillance data, quantifying and estimating accurately the global pediatric burden
of TB has been subject of great debates [55], [56], [57]. Nevertheless, a staggering number
of pediatric pulmonary tuberculosis cases have been encountered. For example, in 1989
the World Health Organization (WHO) claimed that 450,000 deaths in children under 15
years of age occur almost every year [58]. In 2000, an estimated 8.3 million new cases of
tuberculosis and 1.8 million of deaths were reported [56], [59]. In 2014, WHO indicated
that approximately one million new cases occurred among children, of whom 136,000 died
[60]. Though considerable efforts have been recently deployed to control the prevalence and
incidence of TB cases, tuberculosis remains a serious public health challenge.
The exacerbation of chronic pediatric respiratory conditions is generally associated with
unscheduled returns to the emergency department (ED) within 72 hours. By return visits
to the ED, we refer to the definition given by De Sales et al. as the return of a patient to
the ED because of the initial complaint within 72 hours from being discharged [61]. Though
unplanned return visits to the ED are generally related to the progression of the illness [62],
[63], many other factors and scenarios including the quality of the health systems that take
patients in, medical errors, persistence of the parents for extra-care may also be involved
[64], [65]. Another important concern is that ED 72-hour revisits impose burdens not only
on patients and their families, but also to insurance providers. Unscheduled readmissions
may lead to overcrowding of medical facilities and incur financial burdens on hospitals [66],
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[67]. Return to ED rates have been used as a metric to assess the quality care provided
to patients, where higher rates are widely used to designate inappropriate treatments or
eventual medical errors [62]. Today, the rate of return visits to the ED is the metric of
choice for measuring care quality in the ED. In recent literature, a generally accepted rate of
return visit to the ED is estimated to be less than 1% [61]. According to other researchers,
return visit rate ranges between 2.5% and 5.2% for emergency departments [66], [63], [68].
In contrast, [69] indicated that site-specific 72-hour return visit rates ranged from 1.1% to
15.2%. A great number of the previous studies related to the association between chronic
respiratory conditions and the rate of ED return reported some factors such as young age,
health insurance coverage, higher acuity to be the main causes for returning visits to the
ED [70], [66]. Other studies have reported that the greater rate of returning to the ED is
significantly associated to young age [66], [63].
Little research has been conducted to investigate new risk factors for return ED visits for
patients with existing respiratory conditions. Nevertheless, [71] reported that antimicrobial prescription for upper respiratory infections among patients covered by Medicaid has
decreased, and that there is no association between the prescription and the decrease in
subsequent return visits. [63] studied the frequency of pediatric 72-hour return visits to
the ED between 2001 and 2007. A significant increase in the return visit rate was noticed
between 2001 and 2007. The authors also found factors such as age, arrival time to the ED,
recent discharge from the hospital, and some geographical regions of the US to be strongly
associated with return visits to the ED.
In this study, we provided comprehensive analyses of return visits in the pediatric ED settings
among children with chronic respiratory conditions. We identified all statistically significant
respiratory conditions that are predictive for return ED visits among children that have been
discharged within 72 hours. We estimated the magnitude and directions of the effects sizes,
allowing hospitals, healthcare facilities and public health institutions to design and adopt
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a more accurate and advantageous regulation for handling high risk patients. Lastly, we
implemented several machine learning algorithms to find the best predictive model for ED
readmission within 72 hours for children with existing pulmonary conditions.

3.2

Methods

We conducted this multicentered epidemiological study using data queried from the large
Health Facts database. This database is a repository of de-identified medical data from 650
hospitals centers throughout the United States containing complete details of all patient
visits since 2015. The existing data in the database are obtained from electronic medical records, which are also provided by contributing hospitals and organizations. These
records can include encounter data (emergency, outpatient, and inpatient), provider specialty, demographics (age, sex, and race), diagnoses and in-hospital procedures documented
by ICD-9-CM codes, laboratory data, pharmacy data, in-hospital mortality, and hospital
characteristics [72]. While a range of hospitals and other medically related entities from
different horizons around the country collect the data, Cerner Corporation is the principal
representation that mainly captures, centralizes, and stores the data. As of 2018, Health
Facts brings together information from 90 health centers and 650 facilities across the states.
In this study, we however decided to use the International Classification of Diseases, Tenth
Revision, Clinical Modification (ICD-10-CM) to determine patients treated from respiratory
conditions not associated with cancer and as captured by ICD-10-CM codes J00-J99.
We conducted a retrospective case-control study of patients under 18 years of age nested
in the larger cohort of all patients. The selected patients were admitted in 166 emergency
departments. The approval to conduct this was given by the CHOC Children’s Hospital
Institutional Review Board (IRB 180857). The used deidentified dataset contains the admission data of approximately 1.7 million patients that were admitted in pediatric emergency
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departments (EDs). The available demographic variables were race (Caucasian, Hispanic,
African American, and Black, Asian Pacific Islander, Native American, unknown), age and
sex. The demographic variable age was divided into three categories: (0, 5], (5,12], and
(12,18]. Patients whose sex information was not available were excluded from the study.
The type of insurance was used to approximate the individual patient’s socioeconomic status. The patients involved in this study use one of the insurance types (commercial, Medicare
Medicaid, 2 other government insurance types, self-pay, and others). Since chronic respiratory conditions can result in unplanned return to the ED and higher hospital utilization,
related variables were added. The key reason for this is that hospital utilization generally
relates to the efficiency of the care-quality received by patients. As such, the hospital utilization variables used as explanatory variables are Previous ED visit, Ispediatric, Has History
of Return Visit and number of medicines taken by the patient, and length of stay (LOS).
The patient’s length of stay was also divided into four categories: (0, 4], (4,8], (8,16], (16,24].
Some of the most common respiratory conditions coded as Acute Nasopharyngitis[common
cold] (J00), Acute Sinusitis(J01), Acute Pharyngitis (J02), Acute Tonsillitis (J03), Acute
Laryngitis (J04), Acute Obstructive Laryngitis and Epiglottitis (J05), Acute Upper Respiratory Infections of Multiple and Unspecified Sites (J06), Influenza due to certainidentified influentza viruses (J09-J11), Viral Pneumonia, not elsewhere classified (J12), Bacteria
and Other Pneumonia (J13-J18), Acute Bronchitis(J20), Acute bronchiolitis (J21), Vasomotor and Allergic Rhinitis (J30), Chronic Rhinitis, Nasopharyngitis and Pharyngitis (J31),
Chronic Sinusitis (J32), Chronic disease of tonsils amd adenoids (J35), Nasal Polyp Other
Unspecified Disorders Nose Nasal Sinuses (J33-J34), Peritonsillar Abscess (J36), Other diseases of Upper Respiratory tract (J39), Bronchitis, not specified as acute or chronic (J40),
Simple and Mucopurulent chronic bronchitis (J41), Unspecified Chronic Bronchitis (J42),
Emphysema (J43), Asthma (J45), Acute Respiratory Distress Syndrome (J80), Suppurative and Nectrotic of Lower Respiratory Tract (J85-J86), Pleural effusion, plague, and other
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pleural conditions (J90-J92, J94), Intraoperative and Postpreocdural complications and Disorders not classified elsewhere (J95), and Other diseases of the respiratory system (J98-J99
) were included in the study. Table 3.2 displays the prevalence rate of the concerned respiratory conditions. addition, Surgical procedures during the index ED visit were not included
in the study, but they were also classified into auditory, cardiovascular, digestive, integumentary, musculoskeletal, and urinary/reproductive system surgery using the current procedural
terminology code version 4 (CPT-4). Furthermore, we estimated the 90th percentile of
the number of medications administered during the ED visits and categorized patients into
2 groups: patients who received greater than the 90th percentile and those that did not.
Lastly, we excluded data from all ED facilities that have had less than 100 return visits as
they corresponded to facilities with disproportionately small number of encounters and may
be a result of data entry error and noise.
As seasonal variation is known to be also responsible for clinical discomfort to patients
with chronic conditions and an increase of the hospitalization rate and that of return to
ED, we decided to categorize the variable that describes the month at which the patients
were readmitted in ED into 4 categories. Winter (December 1st- February 28th or 29th in
leap year) was mapped to 0, Spring season (March 1st – May 31st) to 1, summer (June
1st – August 31st) to 2, and Autumn (September 1st – November 30th) to 3. Patients
were excluded if they have respiratory condition occurrence rate less than 1,000 and several
medications (> 10). The primary reason for this is to make sure that we include only
facilities that have seen large number of patients with respiratory conditions. The secondary
reason for this selection technique is also exclude noise in the data in relation to ED facilities.
Subjects who also spent more than 24 hours in ED were also dropped in the study.
In the study, the multicollinearity in the data was assessed by estimating the generalized
variance inflation factor (GVIF) of each of the variables. GVIF is a statistical tool that
quantifies the degree of correlation between the predictors present in a given model. One
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mission of GVIF is to identify variables that are highly correlated with each other. Another
mission of GVIF is to be able to assess the contribution of involved variables in the model.
Addressing the degree to which variables are correlated (multicollinearity) improves the measurement of association between a variable within a model and the outcome it is predicting.
This decision was made, a priori, to exclude all variables with GVIF greater than 4 – a rule
of thumb threshold based on previous studies [73], [74], [75].
The data used in this multicentered epidemiologic study were prepossessed HealthDataLab
using Center Corporation – an elastic parallel distributed high-performance cloud computing
platform running on Apache Spark Since our data are clustered by Hospital ID and Patient
ID, a mixed random effects logistic regression model was deployed to conduct a multivariate
analysis. Thus, a random intercept model was built to model the return to the ED within 72
hours, a binary outcome variable. The model building and statistical analysis were preformed
using R statistical Software. The machine learning models were constructed using Python
Computing Programming Language
We implemented 15 high-accuracy machine learning classiication models such as Decision
Tree (DT), K-Nearest Neighbors (KNN), Gaussian Naı̈ve Bayesian (GNB), Multinomial
Naı̈ve Bayesian (MNB), Complement Naı̈ve Bayesian (CNB), Multinomial Logistic Regression (MLR), Multi-Layer Perceptron (MLP), Ridge Regression Classifier (RRC), Linear
Classifiers with Stochastic Gradient Descent (LCSGD), Passive Aggressive Classifier (PAC),
Linear SVC (SVC), Random Forest (RF), Extremely Randomized Trees (ERT), Gradient
Boosting Tree (GBT), and Extreme Gradient Boosting Tree (EGBT) on the task of classifying subjects as patients that have been readmitted, or not readmitted 72 hours after
discharge. Using grid-search, hyper-parameter tuning optimization across different models
was carried out. The optimal values of the hyperparameters were selected based on the AUC
over 10-fold validation datasets. The implementation of the adopted machine learning algorithms and the hyper-parameter tuning were done in python and while using scikit-learn.
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Table 3.1 displays the names of the machine learning algorithms involved in this study, the
names of the considered hyperparameters and the values and options they assume. The
choice of these machine learning algorithms, associated hyperparameters and their values
was inspired by a study recently done by Zhen and colleagues (Zheng et al., 2020).
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Table 3.1: Hyperparameters Table

Model Name

Hyperparameter Name

Hyperparameter Options

DT

criterion

’gini’,’entropy’

splitter

’best’,’random’

max features

’auto’,’sqrt’,’log2’,None

n neighbors

15 31

weights

’uniform’,’distance’

algorithm

’ball tree’,’kd tree’

GNB

var smoothing

10−7∼−12

MNB

alpha

0, 0.1, 0.5, 0.8,1

CNB

alpha

0, 0.1, 0.5, 0.8,1

MLR

solver

’newton-cg’,’lbfgs’,’saga’,’sag’

RRC

alpha

1e-3, 1e-2, 1e-1, 1

solver

’svd’, ’cholesky’, ’lsqr’, ’sparse cg’, ’sag’, ’saga’

loss

’hinge’,’log’,’modified huber’,’squared hinge’,’perceptron’

alpha

1e-3, 1e-2, 1e-1, 1

learning rate

’constant’,’optimal’,’invscaling’,’adaptive’

eta0

0.01, 0.001, 0.0001

C

0.001, 0.01, 0.1,1

loss

’hinge’,’squared hinge’

loss

’hinge’,’squared hinge’

C

0.001, 0.01, 0.1, 1

n estimators

300, 500, 800

criterion

’gini’, ’entropy’

bootstrap

True, False

max features

’auto’, ’sqrt’, ’log2’,None

n estimators

300,500,800

KNN

LCSGD

PAC

SVC

RF

ERT
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GBT

EGBT

MLP

criterion

’gini’, ’entropy’

bootstrap

True, False

max features

’auto’, ’sqrt’, ’log2’,None

loss

deviance, exponential

learning rate

0.1 , 0.01, 0.001, 0.1

subsample

0.1, 0.5, 0.9

n estimators

300, 500, 800

max features

’auto’, ’sqrt’, ’log2’, None

tree method

’auto’, ’exact’, ’approx’, ’hist’

grow policy

’depthwise’, ’lossguide’

n estimators

300, 500, 800

learning rate

0.001, 0.01

max depth

10, 15, 20, 50, 100

hidden layer size

(50,50,50), (50,100,50), (100,)

activation

’tanh’, ’relu’

solver

’sgd’, ’adam’

alpha

0.0001, 0.05

learning rate

’constant’, ’adaptive’

29

Figure 3.1: ED return proportions with respect to patient’s age

3.3

Results

To make inference about the whole enrolled patients and identify statistical and causal
associations between variables that are present in the data at the time of the study and the
ED return within 72-hours after discharge to home, univariate and multivariate analyses are
then performed. As such, refers to Table 3.2, and Table 3.3 for results generated from the
univariate study, and to Table 3.4, and Table 3.5 for outputs obtained from the multivariate
counterpart.
Patients and ED return Rates
In this study, the total sample size was 1,513,333, where the subjects were distributed among
166 hospitals across the nation. A total number of 48,828 (3.23%) returned to ED within
72 hours versus 1,464,505 (96.77%) who did not return to ED at least in the next 72 hours.
Thus, ED readmission is a relative event that induces imbalanced data. Per our modeling
objective, we partitioned the obtained dataset into training and validation sets in 75-25%
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Figure 3.2: Return proportions with respect to the time spent by patients in ED
ratio respectively. The train set was used for learning purposes, while the remainder of the
data was used to validate the models. Exploratory analysis and descriptive statistics of the
demographic and clinical characteristics of the involved subjects present in the training set
are displayed in Table 3.2, and Table 3.3. Among all the eligible patients in the training
set, 46.51% were female while 53.49% were male. Of these patients 42.36% were Caucasian,
31.22% were African American, 7% were Hispanic, 1.24% were Asian Pacific Islander, 2.34%
were Native American and 16% were of non-identified ethnic or racial group(s). Approximately, 57.60% of the eligible subjects were on Medicare or Medicaid versus 23.32% on
Commercial Health Insurance, and 10.77% in other types of insurance. Only 6.03% of the
children were either covered by their family and 2.26% of the patients were under other
governmental insurance. The majority (57.67%) of the patients were 5 years of age or less,
against 29% aged between 5 to 12 and 14% of the encounters older than 12 years of age.
Above all these, the information in the training set indicates that the rate of return to the
emergency department within 72 hours after being discharged was only of 0.032.
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Demographic and Socio-economic Characteristics vs ED Returns
From our statistical analysis, we observed that the readmission rates in male patients is
higher than in female patients as shown in Table 3.2. Strikingly, we found the existence
of a significant (P < 0.001) association between other demographic characteristics such as
participant’s age, length of stay, race/ethnicity, and their medical insurance and ED return
rates. Participants less than 5 years old were the largest number of participants to return
in ED. Figure 3.1, for example, displays the proportion ED returns visit with respect to
patient’s age. Such a proportion follows a quasi-parabolic shape where the maximum number
of unscheduled returns to ED is more pronounced with children that are less than 5 years.
The absolute minimum of such a proportion is achieved among children that are 5 to 10 years.
Though readmission rate to the ED was higher among children older than 5 and less than 12
years of age, it was not as common as with children of less than 5 years of age. The remaining
demographic/Payer/Resourceutilization variables have significant association with pediatric
patients revisiting the ED. It can then be concluded that demographic variables, proxies for
socio-economics status and those for hospital resources are eminent risks factors to the ED
Returns(Figure 3.2).
From our multivariate analysis, we observed that the time spent by patients in the ED during
the last six (6) months is associated with higher odds of returns to the ED. Interestingly, we
discovered that the longer the length of stay, the higher the odds of returns to the emergency
department became. Patients that spent 16 to 24 hours in the ED have 30.4% increase in
odds of return, followed by the ones that spent 8 to 16, and 4 to 8, with 15 and 13% odds of
return. Next to the length of stay, proxies of socio-economic statuses come in term of being
associated with the risk of return to ED. The model reveals that besides patients, regardless
of the type of insurance they own, have an increase in the odds of an unscheduled readmission
to the ED returns. Patients that have insurance of type “others” have the highest increase in
odds (20%), followed by those who have other governmental insurance, Medicare or Medicaid
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with, approximately, 14-, 13-, 4% respectively of likelihood to unexpectedly return to the
ED. Also, we observed that patients that were of ages 5 to 12 had higher drop (22%) in the
odds of a return visit than patients that are older than 12 years of age who present have a
19% drop in odds of a return visit. Furthermore, we examined the importance of race and
ethnicity in the ED. Strikingly, we found that patients of with African American descent
had a 6% decrease in the odds of a return visit. The remaining ethnic group did not display
any statistical significance. Patient’s past hospitalization, previous ED visits and history
of return visits are highly associated with the risk of a return visit. In addition, they all
have an increase in the odds of return visit ranging from 16% to 124%. The free-standing
pediatric ED variable appears to not be statistically significant.
We also found that the number of medications administrated the patients is statistically
and significantly associated with the odds of a return visit in the ED within 72 hours. In
multivariate analysis, we found that patients that are taking more than 3 medications have
almost 40% increase in the odds.
Seasonal effects vs ED Returns
From our examination of seasonal effects and ED returns, we realized that seasonal effects
significantly impact the rates of returning to the ED (Table 3.2). For example, the ED return
visit rate varied by periods of the year. The ED return visit rate is higher in Winter (32%)
followed by ∼19, ∼50 and ∼19% decrease in Spring, Summer and Fall semesters respectively.
However, there is a decrease in the ED return visit rate (∼38%) from Spring to Summer
against an increase of almost 63% between Summer and Fall. Overall, seasonal effects should
be taken as a major cause for patients under 18 to return to the ED. In the multivariate
analysis, we can see a reduction in odds in Spring and Fall (1.2 and 7.2%, respectively)
versus an increase in odds of ED return visit in Summer. Noteworthily, we found that Fall
semester significant risk factor that contributes to the ED return visits.
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Diagnoses vs ED Returns
In the diagnosis and ED return examination, we found that the rate of return to the ED
is significantly (P < 0.001) affected by some types of diagnoses (Table 3.2). For example, besides Mental and Behavioral disorders (F01-F99), Diseases of the nervous system
(G00-G99), Diseases of the musculoskeletal system connective tissue (M00-M99), Pregnancy/Childbirth/Puerperium (O00-O9A), some conditions related to the perinatal period(P00P96) and Congenital and Chromosomal abnormalities(Q00-Q99), the remaining diagnoses
constitute statistically significant (P < 0.001) risk factors to the ED return visits. The rate of
return visits was higher with patients diagnosed with Diseases of the eye and Adnexa (H00H59), infectious/Parasitic diseases (A00-B99) and diseases of the digestive system(K00-K95),
13, 9, and 8%. In multivariate analysis, we found that apart from Congenital chromosomal
abnormalities (Q00-Q99), Injury/Poisoning/Consequences of External Causes (S00-T88),
and Diseases of the eye and Adnexa (H00-H59) and that have 12, 19 and 20% decrease in
odds of return visits, the remaining diagnoses have an increase in odds( between 6 and 71% )
of return visits. Of these diagnoses known as risk factors for patients to return to emergency
department, only infectious/Parasitic diseases (A00-B99), Diseases of the blood and bloodforming organs and certain disorders involving the immune mechanism (D50-D89), Diseases
of the eye and adnexa (H00-H59), Diseases of the digestive system (K00-K95), and Diseases
of the genitourinary system (N00-N99) are statistically significant.
Respiratory Conditions vs ED Returns
In our respiratory conditions and ED returns analysis, we observed that the relationship between respiratory conditions and rate of ED returns is also outlined (Table 3.3). Respiratory
conditions associated with significant ED returns are : Acute sinusitis (J01), Acute pharyngitis (J02), Acute tonsillitis (J03), Acute obstructive laryngitis and epiglottitis (J05), Acute upper respiratory infections of multiple sites (J06), Influenza (J09-J11), Viral pneumonia (J12),
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Bacteria and other pneumonia (J13-J18), Acute Bronchitis (J20), Acute Bronchiolitis (J21),
Vasomotor and allergic rhinitis (J30), Chronic rhinitis/nasopharyngitis/pharyngitis, Chronic
sinusitis (J32), Nasal polyp/other nose or nasal infections (J33-34), Peritonsillar abscess
(J36), Other chronic lower respiratory diseases (J40-J43) and Intraoperative/postprocedural
complications/disorders of the respiratory system (J95). Patients diagnosed with Acute upper respiratory infections of multiple sites (J06) and Acute pharyngitis(J02) had the highest
proportion of returns (37% and 18%, respectively). Alongside these conditions are aligned
Acute bronchiolitis (9%), Nasal poly/other nose or nasal infections (8%), and Bacteria and
other pneumonia (7%) as conditions with high ED revisit rates. In multivariate analyses, patients who suffered from Peritonsillar Abscess (J36), Viral pneumonia, not elsewhere
classified(J12), Acute bronchiolitis (J21), Bacteria and other pneumonia (J13-J18) and respiratory conditions (J90-J92, J94) have higher increase odds (127%, 44%, 39%, 27.3% and
16% respectively) of a return visit.
Patients diagnosed with Acute pharyngitis, Asthma (J45, though not being statistically
significant in univariate case), Acute upper respiratory infections of multiple sites, Acute
nasopharyngitis/common cold have reduced 5, 8, 9, and 10% decrease in the odds of a return
visit. It was also found that certain respiratory conditions such as Acute tonsillitis (J03), resp
(J4044COPD1), Chronic sinusitis (J32) and Acute bronchitis are associated with reduced
odds (10, 11, 14 and 18%, respectively) of a return visit. Conditions like Acute sinusitis (J01),
diseases of upper respiratory (J39), and Chronic diseases of tonsils and adenoids (J35) have
also reduced odds (23, 26, and 28%) of a return visit.
Comorbidities Surgical Procedures vs Returns
As of the association of the simultaneous presence of other chronic diseases or conditions and
the rate of returns, Table 3.2 indicates that the most common causes for unscheduled returns
to ED are Cardiovascular surgery (CPTA:69000-69979), and Urinary/Reproductive system
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surgery (CPT4:50010-58999). They constitute serious risk factors of returning to emergency
department within 72 hours, with rates of returns 48 and 23%, respectively. Though the readmission rates among patients that went through Integumentary surgery (CPT4:10030-19499),
Musculoskeletal surgery (CPT4:20100-29999), Auditory surgery (CPT4:69000 -69979), and
Digestive surgery (CPT4:40490-49999) have higher ED rates of returns (15, 14, 13, and 12%
respectively), they remain variables that are not statically significant. In the multivariate
analysis setting, besides Digestive surgery (CPT4:40490-49999), which is not statistically significant, the remaining surgical procedures were associated with very high risk of return visit.
With Patients that underwent cardiovascular, Integumentary and Urinary/Reproductive system surgery (CPT4:50010-58999), there is at least 49% and at most 80% increase in odds of
return visits.
Table 3.6 exhibits the average AUC of the 10-fold cross validation testing for the 15 machine
learning models chosen in this study. The best performance was achieved by the Extreme
Gradient Boosting model over all the considered tested models with AUC of 0.645. Another
observation is the poor over all performances of the considered machine learning models. This
can be presumably due the inability of machine learning models to effectively predict return
visits given the current data under investigation. Another reason for these comparatively
poor performances could be that return visits may be influenced by factors that are not
clinical in nature but driven by behavioral patterns of the families with these patients.

3.4

Discussion

Unexpected returns to ED within 72 hours after being discharged generate consequential
economic and social damages. Therefore, identifying the associated preeminent risk factors
that could lead to such undesirable situations has been increasingly growing to be a focal
point for parents, medical staff and hospital management as it can, at least, lead to better
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further decisions.
The present study found that despite that male patients have a higher chance of revisiting
ED than female patients; gender is not associated with higher risk for ED return within 72
hours after being discharged. This is consistent with what was found by [19], [76], [77]. Our
model indicates that patient’s age is proportional to the drop rate in the odds of a return
visit to ED. This tells us that younger patients are more likely to revisit the emergency
department. A similar result was reported by [62]. Such a finding is presumably due to
the fact that when children are younger, they are expected to have have a weaker immune
system.
Interestingly, our model indicates that the duration of a single episode of hospitalization
is most likely to be a significant risk factor for ED readmission. Patients that have spent
a longer time have a higher chance of revisiting ED within 72 hours after discharge. This
result could be related to the fact that the time spent in the medical facility could be a good
indicator of unwell the patients could be. Regarding race, African American patients are
more likely to return to the ED within 72 hours more than Caucasian patients. In terms
of insurance type, patients on Medicare/Medicaid or Other governmental insurance or other
types of coverage are more likely to returns to the ED. Our model also indicates that previous
ED visits were a very strong predictor of at-risk patients. In fact, the number of previous
ED visits was found to be proportional to the risk of returning to the ED. Precisely, patients
that have previously visited ED the most are at higher risk of making another return.
In terms of chronic respiratory conditions, we found that patients suffering from complications coded with J01, J06, J09-J11, J13-J18, J20, J21, J31, J36, and J45 are more inclined to
return the the ED within 72 hours after being discharged. Identifying patients that display
these medical complications is of great importance as it can help clinicians to : (1) know
which patients need extra care or special attention, (2) make better orientation decisions,
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(3) determine which patients will need post-ED support, (4) determine what type of support
should be provided to the concerned patients, and (5) educate the patients risks that could
exacerbate their conditions. Nevertheless, it shall be noted that most of the respiratory
diagnoses are unlikely to result in an ED revisit.
In this study, we surprisingly found that the presence of some comorbidities was strongly associated higher chance to unexpectedly return to ED with 72 hours after discharge. We noticed
found that patients that are suffering from Intraoperative and postprocedural complications
and disordered (J95), Cardiocascular surgery (CPT4:33010-19499), Integumentary surgery
(CPT4:10030-19499), Unirary/Reproductive system surgery(CPT4:50010-58999) were inclined to revisit the emergency department unexpectedly.
Arguably, building models, regardless of their nature, involves caveats and limitations that
are generally related to lack of extra information (i.e data), under or over assumption. Similarly, this study suffers from a variety of weaknesses. Firstly, the data used for this investigation is administrative data. This insinuates the presence of eventual coding errors during the
period of assigning diagnosis codes to patients. Secondly, our data set is highly unbalanced
in favor of not returning to the ED within 72 hours after being discharged. Thirdly, it should
be known that despite the broad geographical distribution of the enrolled EDs across the
country, it will be risky to consider the involved population in this study could be taken as
a viable sample representative of all the children undergoing chronic respiratory conditions.
Therefore, the study findings should not be generalized to all the children suffering from
respiratory conditions. Fourthly, the data set that we use for modeling purposes does not
tell us exactly how the patients were enrolled in this study. Plus, we do not have any information about patients’ care during their previous visits. Knowing this may be help orient
the efforts during their next appearance in the emergency department. Fifthly, the cohort
of patients in this study was based on patients discharged home from the ED. This implies
that we missed patients admitted to the hospital through the ED and return to the ED after
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discharge from the hospital. Such a limitation is, however, one of design and related to the
question being asked. In our case, we are concerned in elucidating the difference between
patients who return to the ED and those who do not among patients discharged home from
the ED (and deemed not requiring hospitalization).
Besides the information about the type of insurance used by the patients, no other socioeconomic status is available. For example, the level of education could be used to investigate
the degree of awareness of parents with respect to the utilization of ED resources.
Also, this study suffers from the way the study was designed. For example, our mixed
random effect model enables determine which variables could be seen as major risk factors
of return to the emergency department. However, it does not inform us about which ED
return was avoidable. Another limitation that could come from the study design is that
some of the return visits that were captured may have been unavoidable which we were not
able to capture/establish in this study.
Despite the above highlighted caveats and limitations, the contributions and implications of
this study are noteworthy. This study may help to (1) inform the patients about causes and
risk factors that could lead to a potential exacerbation of their health conditions; (2) educate
parents on the urgency of pediatric conditions; (3) provide EDs with what is necessary to
determine which interventions might be needed; (4) measure the effectiveness of the services
provided by EDs; (3) proffer ways to improve the quality of care of patients at risk; and (4)
construct very solid future strategies that could help drastically reduce potential avoidable
ED return visits.
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3.5

Conclusion

This multicenter study of pediatric return visits within 72 hours among patients with respiratory conditions across 166 emergency departments established that revisits within such
short period of time may be driven more by non-respiratory comorbidities than the underlying respiratory conditions. This pattern may differ as the window is increased to a value
greater than 72 hours. However, peritonsillar abscess, pneumonia, and bronchiolitis exposes
pediatric patients to higher odds of return visit. These findings indicate that ED providers
should pay closer attention to the respiratory risk factors as well as the comorbid conditions
that patients with respiratory conditions may present with. Corresponding improvements in
the quality of care and in the education of patients and their families may result in reductions
in return visits to the ED.

3.6

Summary

Understanding and dealing effectively with complex processes, such as emergency department
(ED) return visits, in order to better predict and efficiently minimize associated risks have
been the subject of virulent debates and the ground of countless arguments. In the past few
decades, academics, health management experts and insurance companies have proposed a
forest of techniques for reaching a better destination with respect to with ED return visits.
Among other approaches, predicting patients that are more likelihood to have ED return
visits has become one of the principal concerns. In this light and in the spirit of taking part
of this concert, we intended to identify respiratory conditions and associated comorbidities
most likely to result in a return visit among children discharged home from the ED. For this,
special attention was given to univariate and multivariate analyses and machine learning
consideration. The univariate study was performed in analyzing the summary statistics of
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the eligible population. The multivariate analysis was conducted in using a nested mixed
effects model, with the aim of modeling the return to ED within 72 hours such that the
ED facilities are random intercepts and patients nested within the facilities. The machine
learning consideration was executed by hyper-tuning 15 classifiers.
It resulted from the study that unexpected return visits to the ED among children undergoing
respiratory is statistically and significantly associated with conditions such as Acute bronchiolitis [odds ratio and 95% confidence interval: 1.39 (1.35, 1.44)], pneumonia [1.22 (1.18,
1.27)], and asthma [1.07 (1.04, 1.10)]. In addition, we found that over 80% of non-respiratory
comorbid classes of diseases are associated with increased risk of return visits.
Furthermore, we found that machine learning models are not imperatively suited for predicting return visits as these could be influenced by factors that are related to behavioral
patterns of the families with the patients.
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Table 3.2: Univariate Summary Statistics (USS)

Variable

Levels

No return

Had return

Chi-

visit

visit

squared

N (%)

N (%)

p value

Resource Utilization, Medications, and Season
[0,4)

934976 (85.15)

30572 (83.21)

[4,8)

106997 (9.74)

4215 (11.47)
< 0.001

ED length of stay (hours)
[8,16)

41631 (3.79)

1394 (3.79)

[16,24)

14428 (1.31)

558 (1.52)

0

674715 (61.45)

17544 (47.75)

1

252210 (22.97)

9477 (25.80)

Previous ED Visit

< 0.001
2

99013 (9.02)

4567 (12.43)

3 or more

72094 (6.57)

5151 (14.02)

No

1047164 (95.37)

34104 (92.83)

Previous hospitalizations (prior
6 months)

< 0.001
Yes

50868 (4.63)

2635 (7.17)

No

1038850 (94.61)

32619 (88.79)

Has History Of Return Visit

< 0.001
Yes

59182 (5.39)

4120 (11.21)

No

679870 (61.92)

21307 (58.00)

Free-standing pediatric ED

Number of medications greater

< 0.001
Yes

418162 (38.08)

15432 (42.00)

No

1060102 (96.55)

34853 (94.87)
< 0.001

than 90th percentile
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Yes

37930 (3.45)

1886 (5.13)

Winter

350208 (31.89)

12114 (32.97)

Spring

284611 (25.92)

9628 (26.21)

Season

< 0.001
Summer

177002 (16.12)

6081 (16.55)

Fall

286211 (26.07)

8916 (24.27)

Comorbid Diagnoses
Certain infectious and parasitic

No

1008346 (91.83)

33356 (90.79)
< 0.001

diseases (A00-B99)

Yes

89686 (8.17)

3383 (9.21)

No

1096685 (99.88)

36653 (99.77)

Neoplasms (C00-D49)

< 0.001

Diseases of the blood and blood-

Yes

1347 (0.12)

86 (0.23)

No

1091372 (99.39)

36275 (98.74)
< 0.001

forming organs and certain disorders involving the immune mech-

Yes

6660 (0.61)

464 (1.26)

No

1083629 (98.69)

36060 (98.15)

anism (D50-D89)

Endocrine,

nutritional

and

metabolic diseases (E00-E89)
Mental, Behavioral and Neu-

< 0.001
Yes

14403 (1.31)

679 (1.85)

No

1083399 (98.67)

36171 (98.45)

rodevelopmental disorders (F01-

< 0.001

F99)

Yes

14633 (1.33)

568 (1.55)

Diseases of the nervous system

No

1069382 (97.39)

35721 (97.23)

(G00-G99)

Diseases of the eye and adnexa
(H00-H59)

0.058
Yes

28650 (2.61)

1018 (2.77)

No

933720 (85.04)

31914 (86.87)
< 0.001

Yes

164312 (14.96)
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4825 (13.13)

Diseases of the circulatory system (I00-I99)

Diseases of the digestive system
(K00-K95)

Diseases of the skin and subcutaneous tissue (L00-L99)
Diseases of the musculoskele-

No

1091760 (99.43)

36416 (99.12)
< 0.001

Yes

6272 (0.57)

323 (0.88)

No

1055944 (96.17)

34980 (95.21)
< 0.001

Yes

42088 (3.83)

1759 (4.79)

No

1069817 (97.43)

35611 (96.93)
< 0.001

Yes

28215 (2.57)

1128 (3.07)

No

1077523 (98.13)

36100 (98.26)

tal system and connective tissue

0.076

(M00-M99)

Yes

20509 (1.87)

639 (1.74)

Diseases of the genitourinary sys-

No

1082372 (98.57)

36051 (98.13)

tem (N00-N99)

Pregnancy, childbirth and the
puerperium (O00-O9A)

Certain conditions originating in
the perinatal period (P00-P96)
Congenital malformations, de-

< 0.001
Yes

15660 (1.43)

688 (1.87)

No

1097151 (99.92)

36689 (99.86)
< 0.001

Yes

881 (0.08)

50 (0.14)

No

1094492 (99.68)

36612 (99.65)
0.467

Yes

3540 (0.32)

127 (0.35)

No

1091627 (99.42)

36481 (99.30)

formations and chromosomal abnormalities (Q00-Q99)
Injury, poisoning and certain

0.004
Yes

6405 (0.58)

258 (0.70)

No

1064455 (96.94)

35840 (97.55)

other consequences of external
causes (S00-T88)

< 0.001
Yes

33577 (3.06)

899 (2.45)

Surgical Procedures
Auditory surgery (CPT4: 69000-

No

1096616 (99.87)

36698 (99.89)
0.401

69979)
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Cardiovascular surgery (CPT4:

1416 (0.13)

41 (0.11)

No

1092786 (99.52)

36413 (99.11)
< 0.001

33010-37799)

Digestive surgery (CPT4: 40490-

Yes

5246 (0.48)

326 (0.89)

No

1096760 (99.88)

36698 (99.89)
0.875

49999)

Integumentary surgery (CPT4:

Yes

1272 (0.12)

41 (0.11)

No

1096378 (99.85)

36654 (99.77)
< 0.001

10030-19499)

Musculoskeletal surgery (CPT4:

Yes

1654 (0.15)

85 (0.23)

No

1096460 (99.86)

36705 (99.91)
0.014

20100-29999)

Urinary/Reproductive

Yes

system

surgery (CPT4: 50010-58999)

Yes

1572 (0.14)

34 (0.09)

No

1095484 (99.77)

36540 (99.46)
< 0.001

Yes

2548 (0.23)

199 (0.54)

Table 3.3: USS Continuation

Variable

No return

Had return

Chi-

visit

visit

squared

N (%)

N (%)

p value

Levels

Demographics

Age, y

[0, 5)

630446 (57.42)

24049 (65.46)

[5, 12)

317500 (28.92)

8389 (22.83)

[12 or older)

150086 (13.67)

4301 (11.71)

Female

510656 (46.51)

16632 (45.27)

Sex

< 0.001

< 0.001
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Male

587376 (53.49)

20107 (54.73)

Commercial

256720 (23.38)

7967 (21.69)

Medicare or

631730 (57.53)

21966 (59.79)

Medicaid

Payer

< 0.001

Other

24822 (2.26)

827 (2.25)

Self-Pay

66465 (6.05)

1987 (5.41)

Others

118295 (10.77)

3992 (10.87)

Caucasian

465203 (42.37)

15563 (42.36)

African

343185 (31.25)

11165 (30.39)

Hispanic

76179 (6.94)

2564 (6.98)

Asian Pacific

13668 (1.24)

486 (1.32)

25517 (2.32)

1059 (2.88)

174280 (15.87)

5902 (16.06)

governmental

American
Race and/or ethnicity

< 0.001

Islander
Native
American
Other

Respiratory conditions
Acute nasopharyngitis [common
cold] (J00)

No

1068164 (97.28)

35829 (97.52)
0.005

Yes

29868 (2.72)

910 (2.48)

No

1089198 (99.20)

36531 (99.43)

Acute sinusitis (J01)

< 0.001
Yes

8834 (0.80)

208 (0.57)

No

872131 (79.43)

30176 (82.14)

Acute pharyngitis (J02)

< 0.001
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Yes

225901 (20.57)

6563 (17.86)

No

1048445 (95.48)

35385 (96.31)

Acute tonsillitis (J03)

< 0.001

Acute laryngitis and tracheitis

49587 (4.52)

1354 (3.69)

No

1096471 (99.86)

36686 (99.86)
0.972

(J04)

Acute

Yes

obstructive

laryngitis

[croup] and epiglottitis (J05)
jAcute upper respiratory infec-

Yes

1561 (0.14)

53 (0.14)

No

1038772 (94.60)

34513 (93.94)
< 0.001

Yes

59260 (5.40)

2226 (6.06)

No

683091 (62.21)

23327 (63.49)

tions of multiple and unspecified

< 0.001

sites (J06)

Yes

414941 (37.79)

13412 (36.51)

Influenza due to certain identi-

No

1057642 (96.32)

35543 (96.74)

fied influenza viruses (J09-J11)

Viral pneumonia, not elsewhere

Yes

40390 (3.68)

1196 (3.26)

No

1096551 (99.87)

36649 (99.76)
< 0.001

classified (J12)

Bacteria

< 0.001

and

Other

Pneumonia(J13-J18)

Yes

1481 (0.13)

90 (0.24)

No

1044872 (95.16)

34173 (93.02)
< 0.001

Yes

53160 (4.84)

2566 (6.98)

No

1073771 (97.79)

36112 (98.29)

Acute bronchitis (J20)

< 0.001
Yes

24261 (2.21)

627 (1.71)

No

1038129 (94.54)

33336 (90.74)

Acute bronchiolitis (J21)

Vasomotor and allergic rhinitis
(J30)

< 0.001
Yes

59903 (5.46)

3403 (9.26)

No

1073407 (97.76)

36226 (98.60)
< 0.001

Yes

24625 (2.24)
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513 (1.40)

Chronic rhinitis, nasopharyngitis

No

1094025 (99.64)

36647 (99.75)
< 0.001

and pharyngitis (J31)

Yes

4007 (0.36)

92 (0.25)

No

1081559 (98.50)

36290 (98.78)

Chronic sinusitis (J32)

< 0.001

Chronic diseases of tonsils and

ified

Polyp

16473 (1.50)

449 (1.22)

No

1095590 (99.78)

36680 (99.84)
0.015

adenoids (J35)
Nasal

Yes

Other

Disorders

Unspec-

Nose

Yes

2442 (0.22)

59 (0.16)

No

998423 (90.93)

33687 (91.69)

Nasal

Sinuses(J33-J34)

< 0.001
Yes

99609 (9.07)

3052 (8.31)

No

1097063 (99.91)

36664 (99.80)

Peritonsillar abscess (J36)

Other diseases of upper respiratory tract (J39)

< 0.001
Yes

969 (0.09)

75 (0.20)

No

1096467 (99.86)

36698 (99.89)
0.1387

Yes

1565 (0.14)

41 (0.11)

No

1073593 (97.77)

36053 (98.13)

COPD (J40-J44)

< 0.001
Yes

24439 (2.23)

686 (1.87)

No

896664 (81.66)

30209 (82.23)

Asthma (J45)

Acute respiratory distress syndrome (J80)
Suppurative and nectrotic condi-

0.006
Yes

201368 (18.34)

6530 (17.77)

No

1096515 (99.86)

36688 (99.86)
1.000

Yes

1517 (0.14)

51 (0.14)

No

1097105 (99.92)

36710 (99.92)

tions of lower respiratory tract
(J85-J86)

0.791
Yes

927 (0.08)
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29 (0.08)

Pleural effusion, plague, and

No

1096757 (99.88)

36686 (99.86)

other pleural conditions (J90J92, J94)
Intraoperative and postprocedu-

0.140
Yes

1275 (0.12)

53 (0.14)

No

1096176 (99.83)

36638 (99.73)

ral complications and disorders

< 0.001

not classified elsewhere (J95)

Yes

1856 (0.17)

101 (0.27)

Other diseases of the respiratory

No

1082079 (98.55)

36175 (98.46)

system (J98-J99)

0.203
Yes

15953 (1.45)
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564 (1.54)

Table 3.4: Results of the Mixed Effects Models(MEM)

Variable

Levels

Odds Ratio

[0,4)

Reference

[4,8)

1.131 (1.091, 1.173)

ED Length of stay (hours)

p value

< 0.001
[8,16)

1.149 (1.070, 1.235)

[16,24)

1.304 (1.181, 1.440)

0

Reference

1

1.367 (1.332, 1.403)

Previous ED Visit

< 0.001
2

1.606 (1.551, 1.663)

3 or more

2.244 (2.161, 2.331)

Yes

1.202 (1.152, 1.255)

< 0.001

Has History Of Return Visit

Yes

1.158 (1.114, 1.204)

< 0.001

Number of medications greater than

Yes

1.399 (1.33, 1.471)

< 0.001

Winter

Reference

Spring

0.988 (0.961, 1.015)

0.381

Summer

1.014 (0.982, 1.047)

0.393

Fall

0.928 (0.902, 0.955)

< 0.001

Previous

hospitalizations

(prior

6

month)

90th percentile

Season

Comorbid Diagnoses
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Yes

1.706 (1.528, 1.905)

< 0.001

Yes

1.511 (1.127, 2.025)

0.006

Neoplasms (C00-D49)

Yes

1.385 (1.100, 1.744)

0.006

Diseases of the circulatory system (I00-

Yes

1.241 (1.080, 1.427)

0.002

Yes

1.233 (1.131, 1.343)

< 0.001

Yes

1.184 (1.083, 1.296)

< 0.001

Yes

1.134 (1.077, 1.194)

< 0.001

Yes

1.120 (1.050, 1.194)

0.001

Yes

1.112 (1.019, 1.214)

0.017

Yes

1.102 (1.062, 1.143)

< 0.001

Yes

1.100 (1.026, 1.179)

0.007

Diseases of the blood and bloodforming organs and certain disorders involving the immune mechanism (D50D89)
Pregnancy, childbirth and the puerperium (O00-O9A)

I99)
Diseases of the genitourinary system
(N00-N99)
Mental, Behavioral and Neurodevelopmental disorders (F01-F99)
Diseases of the digestive system (K00K95)
Diseases of the skin and subcutaneous
tissue (L00-L99)
Endocrine, nutritional and metabolic
diseases (E00-E89)
Certain infectious and parasitic diseases
(A00-B99)
Diseases of the nervous system (G00G99)
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Injury, poisoning and certain other con-

Yes

0.810 (0.754, 0.870)

< 0.001

Yes

0.804 (0.779, 0.830)

< 0.001

1.832 (1.461, 2.296)

< 0.001

1.603 (1.381, 1.860)

< 0.001

1.491 (1.324, 1.678)

< 0.001

0.725 (0.526, 0.999)

< 0.001

sequences of external causes (S00-T88)
Diseases of the eye and adnexa (H00H59)
Surgical Procedures
Integumentary surgery (CPT4: 1003019499)
Urinary/Reproductive system surgery
(CPT4: 50010-58999)
Cardiovascular surgery (CPT4: 3301037799)
Digestive surgery (CPT4: 40490-49999)

Table 3.5: MEM Continuation

Variable

Age, y

Payer

Level

Odds ratio (95% CI)

p value

[0, 5)

Reference

[5, 12)

0.782 (0.760, 0.804)

[12 or older)

0.816 (0.786, 0.848)

Commercial

Reference

Medicare or

1.127 (1.092, 1.163)

< 0.001

1.142 (1.059, 1.232)

< 0.001

< 0.001

Medicaid
Other
governmental
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Self-Pay

1.042 (0.988, 1.098)

0.128

Others

1.202 (1.149, 1.257)

< 0.001

African American

0.940 (0.912, 0.969)

< 0.001

Hispanic

0.964 (0.919, 1.011)

0.134

Asian Pacific

1.054 (0.959, 1.159)

0.274

Native American

0.928 (0.835, 1.031)

0.165

Other

1.017 (0.982, 1.054)

0.339

Female

Reference

Male

1.025 (1.003, 1.047)

0.024

Caucasian

Race and/or ethnicity

Islander

Sex

Respiratory risk factors
Peritonsillar abscess (J36)

Yes

2.266 (1.775, 2.892)

< 0.001

Viral pneumonia, not elsewhere

Yes

1.436 (1.155, 1.785)

0.001

Yes

1.390 (1.332, 1.449)

< 0.001

Yes

1.273 (1.216, 1.333)

< 0.001

classified (J12)
Acute bronchiolitis (J21)
Bacteria

and

Other

Pneumonia(J13-J18)
Other respiratory conditions
Acute pharyngitis (J02)

Yes

0.948 (0.915, 0.982)

0.003

Asthma (J45)

Yes

0.924 (0.894, 0.956)

< 0.001
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Yes

0.910 (0.885, 0.936)

< 0.001

Yes

0.907 (0.845, 0.975)

< 0.001

Acute tonsillitis (J03)

Yes

0.896 (0.844, 0.950)

< 0.001

COPD (J40-J44)

Yes

0.888 (0.820, 0.961)

0.003

Influenza due to certain identi-

Yes

0.881 (0.828, 0.939)

< 0.001

Yes

0.875 (0.840, 0.911)

< 0.001

Chronic sinusitis (J32)

Yes

0.859 (0.779, 0.946)

< 0.001

Acute bronchitis (J20)

Yes

0.819 (0.754, 0.890)

< 0.001

Acute sinusitis (J01)

Yes

0.768 (0.667, 0.884)

< 0.001

Chronic diseases of tonsils and

Yes

0.724 (0.558, 0.939)

0.015

Yes

0.683 (0.624, 0.748)

< 0.001

Yes

0.665 (0.540, 0.820)

< 0.001

Yes

0.641 (0.491, 0.837)

0.001

Acute upper respiratory infections of multiple and unspecified
sites (J06)
Acute nasopharyngitis [common
cold] (J00)

fied influenza viruses (J09-J11)
Nasal
ified

Polyp

Other

Disorders

Nose

UnspecNasal

Sinuses(J33-J34)

adenoids (J35)
Vasomotor and allergic rhinitis
(J30)
Chronic rhinitis, nasopharyngitis
and pharyngitis (J31)
Intraoperative and postprocedural complications and disorders
not classified elsewhere (J95)
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Table 3.6: Performance of Machine Learning Models

Model Name

AUC Values

DCT

0.514

KNN

0.532

GNB

0.535

MNB

0.532

CNB

0.546

MLR

0.548

RRC

0.546

LCSGD

0.553

PAC

0.534

SVC

0.544

RF

0.546

ERT

0.542

GBT

0.558

EGBT

0.645

MLP

0.519
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4

General Pediatric Models for
Understanding and Predicting Prolonged
Hospital Length of Stay

The impact of the deterioration in the health of a child requiring hospitalization on the family
is multifaceted. It encompasses social, economic, and psychological impressions. To alleviate
those burdens, considerable efforts have been deployed, with the ultimate goal of improving
the healthcare system, the organizational management of modern hospitals and improving
the quality of care delivered to patients. Some pediatric hospitals address these concerns by
creating departments such as Child Life to improve pediatric patients, especially that of the
young child. The length of stay (LOS) in the emergency department (ED) patients has been
found to be a top priority for hospitals and health systems.
Traditionally, ED length of stay (LOS) has been used as an accurate metric to assess the
efficiency of ED management, patient quality, patient quality of care, and functional evaluation [78], [79]. In fact, it has generally been accepted that shorter LOS is associated with
more efficient and effective care [80]. Based on the existing standards, it has been suggested
that an appropriate median ED holding time should be of 2.0 hours for a hospital bed (1.5
hours for an intensive care unit (ICU)) [81]. For [82], patients presenting to the ED should
receive a decision in a maximum of 6 hours after admission to the ED and leave ED at this
time. The shorter a patient stays in the ED, the smaller the chance of developing infections
is [79]. Also, reduced ED LOS is associated with decreased mortality, drastic reduction of
the social costs, and financial burdens not only on patients but also on medical services [83],
[84]. Furthermore, reduced LOS can avoid unnecessary expenses and free up beds for other
critically ill patients.
In contrast, longer ED LOS can result in exposing patients to serious healthcare-acquired
infections, higher mortality rates, and imposing noticeable increase in the total social and
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financial related costs. The impact of prolonged length of stay transcends the child’s experience to that of the family and the hospital facility itself. Longer length of stay may result
in reduced working hours of a parent or guardian, lost productivity at work, and increased
psychological and financial burden on the family. Parents struggle to pay for prolonged care,
which has an impact on their current and future financial security that in turn affects their
children. A 3-year study of hospital resource utilization related to childhood cancer from
2005 found the cumulative charges reaching $16 million, which is about $100,000 per child
in the study [85]. In addition, 50% of those charges were in the first four and a half months
of diagnosis and those charges surprisingly were distributed among only 12.7% of patients
[85]. These patients had worse diagnoses and underwent a multitude of treatments. Parents
of children with a cancer diagnosis, even with insurance, accrue a significant bill to pay
for the treatment. The children themselves are likely to endure difficult mental health and
physical challenges as their LOS increases. In addition, providers and hospital facilities are
more likely to experience revenue leakage as well as challenges with adjudicating medical
claims for treatment offered. It is therefore imperative for the hospitalized child, the family,
providers, and the hospital to reduce unnecessarily prolonged LOS.
One of the most significant issues of ED prolonged LOS is overcrowding. ED overcrowding
has recently become a worldwide concern. ED overcrowding may result in creating many
problems patients and staff, increasing the waiting times and the ED resource utilization,
augmenting the length of stay, portending to an increase of errors and patient mortality, and
inflicting serious financial losses to hospitals [86], [87], [88].
Several studies have been conducted to determine risk factors of longer LOS. Internal and
external factors such as patient characteristics, ED staffing, health care providers, time of
patients arrival, diagnostic methods as well as hospital resource utilization, allocation, and
administration have strongly been associated with ED prolonged length of stay [81], [89], [87],
[79]. The impact of malnutrition [90], hyponatremia [91], febrile neutropenia [92], clinical

57

pathways [84], [93] and weekend admission [94] on hospital length of stay are among the
studies conducted with the ambition to well understand eventual factors that contribute to
ED process times and patient care delays. An 18-year study from 2018 on a healthcare
center in Mexico assessed several sociodemographic and disease-specific differences for a
patient’s LOS [79] Oncology patients often require more hospitalizations during treatment
than patients with most other conditions. A study on the LOS of cancer patients in Brazil
explored the association between demographics and clinical attributes with LOS within the
first year of outpatient treatment [95].
In this study, we addressed the identification of novel risk factors for prolonged LOS using advanced statistical analysis and the prediction of patients most likely to experience prolonged
LOS using machine learning on a large multicenter electronic medical records database. The
goal of this study is to use data captured during the first 24 hours of admission to predict
patients with LOS greater than 2 weeks. The first 24 hours of hospitalization of a child
has yielded critical information to predict LOS [75]. Obviously, appropriate LOS depends
on diagnoses, severity of illness, and a host of complex clinical considerations. We chose a
2-week threshold because it is much greater than the average pediatric length of stay and
falls between the 90th and 95th percentile of general pediatric LOS.

4.1

Methods

Dataset, Clinical Admission, and Patient Encounter
This investigation was approved by the Institutional Review Board of CHOC Children’s
(#180857). A retrospective, population-based cohort study using the Cerner Health Facts
Database for the US-based patients is conducted. The Cener Health Facts database is a
de-identified patient database that provides records about patients coming from different
participating health institutions. The database contains time-stamped and sequenced infor-
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mation on pharmacy, laboratory, admission and billing data from all patient care locations.
In addition, Cener Health Facts database captures information demographic, hospital admissions and discharge, and diagnostic procedures. As of 2018, the Health Facts database was
composed of records of more than 65 million patients provided by over 100 US healthcare
systems and over 650 facilities, more than 500 million encounters, approximately more than
500 million encounters, and 4.7 billion laboratory results. For the sake of confidentiality and
compliance with HIPAA privacy regulations, patient names are omitted and a unique identification number is assigned to each single patient, which is systematically available to all
the participating health institutions. Structurally, Cener Health Facts database stores and
retrieves data that is represented in smaller databases or tables. The database is available
to researchers at healthcare systems that contribute data to it. In 2020, the database was
upgraded and reconstituted as the Cerner Real World Data [96].
We retrieved all pediatric encounters (patients less than 18 years) from the database and
excluded encounters that occurred during the first 6 months of the very first encounter
for each hospital. This exclusion was necessary to ensure that encounters in each hospital
have a 6-month history for variables capturing patients’ history. Furthermore, we excluded
all encounters with LOS less than 24 hours to ensure that all qualifying encounters had a
minimum of 24 hours LOS and data within the first 24 hours of the admission. An additional
exclusion by hospital facility was carried out by excluding all facilities with less than 1000
encounters. The qualifying hospitals contributed data from different periods between 2001
and 2017. We calculated the average age of patients seen at each hospital and classified
those less than 18 years as free-standing pediatric hospitals.
We retrieved data on patient demographics, payer, medications administered during the
first 24 hours of admission, type of admission, and previous healthcare utilization 6 months
prior to the encounter start date. The variable race/ethnicity was divided into 6 groups:
Caucasian, Hispanic, Black/African American, Asian/Pacific Islander, Native American and
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Other/Unknwon. The type of insurance covering the patients were: commercial, governmental (Medicare, Medicaid), other overnmental (Champus, etc), self pay, and otner. All
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
codes in the database were converted to the Tenth Revision (ICD-10-CM) using appropriate translation tables and merged with the original ICD-10-CM data from the most recent
encounters. In order to automatically capture the largest number of the most prevalent pediatric conditions as variables for the study, we retrieved the three-digit level of all ICD-10
diagnoses. This, however, introduced very rare encounters that may result in issues with
statistical separability as well as impact the value of corresponding findings. Consequently,
we set an a priori threshold for including a three-digit level diagnosis at an incidence rate
of 1%. In other words, only such diagnoses occur in 1% or greater was included. These
considerations also help in reducing the risk of modeling challenges due to statistical class
separability which may result in inflated effect sizes or inestimable parameters [97]. We
defined the outcome variable, prolonged LOS, as any LOS greater than 2 weeks.
Outliers in continuous variables may negatively affect statistical and machine learning models. We handled outliers excluding by records wherein the value of a continuous variable
was greater than the 99.5th percentile. We checked for multicollinearity between variables
by estimating the generalized variance inflation factor (GVIF) that measures the degree to
which correlation between variables in a model result in inflated variances [98] We set an a
priori threshold of 4 for the GVIF wherein all variables with GVIF greater than the threshold
is removed in a stepwise manner until all variables have GVIF less than 4 [75] We split the
data into two equal halves by patients.
Statistical Analysis
A two-stage statistical analysis study is implemented using ED LOS as outcome variable of
interest. First, we descriptively described the data via a summary statistics. Second, we built
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a statistical model for inference using a mixed effects logistic regression model where hospitals
were modeled as random intercepts with patients nested within them. Mixed models are an
extension of the traditional linear models which at its core incorporate random and fixed
effects. Mixed models (MM) are well suited describing analysis of clustered or longitudinal
nominal or ordinal response data [99]. They are most useful when working with hierarchical
data which often exude some degree of dependency (within-subjects designs /longitudinal
data). An example would be subjects being sampled from within doctors. MM systematically
accounts for within subjects variability thus, working around ANOVA assumption that data
points are independent of one another [100]. MM are also efficient at analyzing data that
are non-independent and correlated. MM address the correlation issue and does not violate
the linear model’s assumption- independence of observations.
To put MM at work, we started with a full model with all variables as well as 2 two-way
statistical interactions: (1) between age and diagnoses, and (2) between the number of
medications and diagnoses. The selection of these interaction terms was inspired the need
to capture difference in disease progression by age and by severity of illness. We selected
the number of medications administered during the first 24 hours as a proxy for severity of
illness since there are no standard measures of severity.
Given the fact numerous statistical models, such as mixed effects model, have serious problems with handling very complex and non-linear interactions among predictors themselves
as well as with the target variable, it is worth the efforts to trying other robust models.
Thus, to further the study, we used the extreme gradient boosting (XGBoost) to assess
higher level interactions beyond the 2-way statistical interactions(for example 3 or more)
considered in the mixed effects model. Extreme gradient boosting is a variant of of the
Gradient Boosting Machine. Virtually, XGBoost aims at using an ensemble of weak learners
that are sequentially trained in the sake of having a stronger classifier or regresser model.
A meta-optimization task was performed by tuning some hyperparameters, which make the
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ensemble training controllable. This was indeed done with cross validation technique for
assessing how the results of a model will perform on an unseen data. Table 4.1 displays the
values assumed by the involved hyperparameters.
Table 4.1: Parameter grid for hyperparameter tuning of the
extreme gradient boosting model

Hyperparameter

Values

Significance

Boosting operations/iterations

64

Number of boosting operations
is equivalent to the number of
trees built. We chose 64 based
on previous experience on the
minimum number of boosting
iterations required

Learning rate

0.2, 0.3, 0.5, 0.8

Relating to how fast the model
learns. Smaller values help to
prevent overfitting

Maximum tree depth

4, 6, 8

The depth of each tree which
controls the complexity of the
model and interactions explored

Minimum child weight

0, 1, 2, 4

Relating to how partitions are
made on a child node. Larger
values create more conservative
models

Gamma

0, 1, 2, 4

Relating to how leaf node
partitions with respect to
changes in loss. Larger values
result in more conservative
models
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Figure 4.1: LOS with respect to patient’s gender

Numerous metrics such as the area under the receiver characteristics curve (AUROC), the
area under the precision-recall curve (AUCPR), and the values of model sensitivity, positive
predictive value, negative predictive value, F1 score, and the number needed to evaluate (as
the number of patients that will be flagged at-risk before a true positive prediction) were
used to evaluate the performance of both the statistical mixed effects regression and machine
learning models.

4.2

Results

Exploratory Data Analysis : Free-standing Pediatric and Mixed Medical Facilities
Sixty medical centers met the inclusion criteria for hospitals. Of the medical centers used in
this study, nine (9) were free-standing pediatric hospitals, with the remainder being mixed
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medical centers. The 9 free-standing pediatric hospitals contributed ∼51% of all encounters
in the study thereby accounting for the longest period and the greatest number of daily
pediatric admissions.
Exploratory Data Analysis: Length of Stay Class
A total of 700,00 patients with ∼1,000,000 encounters met the inclusion criteria for encounters. The rate of prolonged LOS was 5.0% across all patients and their encounters. The
mean age of the patients was 5 years. Interestingly from the data, we observed that female
patients account for ∼47.3% of LOS class 1 while male subjects were ∼54.1% of LOS class 2
(Figure 4.1). From the within group percentage of both LOS classes high cases of emergent
admissions were observed, with LOS 1 and LOS 2 accounting for 83.7% and 85% of the total
number of patients Figure 4.2.
Expectedly, the combination of commercial and governmental health insurance accounted
for over 60% of all patients coverage plans while 2.2% and 1.8% of the patients paid out of
pocket in both LOS classes (Figure 4.3). From the withing group percentage of patients, we
observed that there were nearly as many children as adults in LOS 1 with children accounting for ∼50.4% of all patients, whereas there was a 3/2 ratio of children to adults in LOS 2,
where adults account for ∼40.8% (Figure 4.4). Furthermore, we explored the ethnicity/race
distribution of the patients. Notably, patients with Caucasian background accounted for
approximately half of all races represented in both LOS classes. Patients of African descent
accounted for ∼20% of all patients. Strikingly, ∼20% of the subjects’ ethnicity were undisclosed while patients of Hispanic, Asian, Native American origin accounting for ∼4%, ∼2%,
and ∼2% of all LOS 1 and LOS 2 subjects (Figure 4.5).
Descriptively (Table 4.5), we surprisingly found that apart from variables (11) including
Overweight and obesity (E66), Scoliosis (M41), Pervasive developmental disorders (F84),
Pneumonia, unspecified organism (J18), Other and unspecified soft tissue disorders, not

64

Figure 4.2: LOS with respect to Emergent Admission

elsewhere classified (M79), Other symptoms and signs involving the circulatory and respiratory system (R09), Fever of other and unknown origin (R50), Headache (R51), Liveborn
infants according to place of birth and type of delivery (Z38), Family history of other specific
disorders (Z83), and Personal risk factors, not elsewhere classified (Z91), there is existence a
significant (P < 0.001) association between the prevalence of prolonged LOS in emergency
department and the remaining variables which constitute the data set.
Multivariate Analysis : mixed effects model
In this retrospective multi-centered study, a mixed effects model (with hospitals as random
intercepts and patients nested within hospitals) was constructed to evaluate the association
between LOS and the involved independent variables in the ED settings. The results obtained
from MM are shown in Table 4.6. It was found that a statistically significant association
between such as variables patient demographics, healthcare utilization variables, certain
diagnoses without interactions, certain interactions between age and diagnoses, and certain
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Figure 4.3: LOS with respect to insurance cover

interactions between number of medications and diagnoses, and prolonged length of stay
exists.
Variables with no interaction(s)
Male patients were significantly more likely to have prolonged LOS with a 6.7% increase in
the odds. Compared to the baseline group of patients that have commercial health insurance, patients that have governmental insurance (Medicare, Medcaid) or any other types
of government insurances (Champus, etc) have higher odds of experiencing prolonged LOS
with increases 35% and 21% respectively. Similarly, self-insured patients have 35% higher
odds of prolonged LOS compared to commercially insured patients. Patients that possess
other health insurance or coverage have 34% higher odds than the baseline group of patients. Compared to Caucasian, patients from other races/ethic groups have higher odds
of experiencing prolonged LOS with increases of approximately 0.04-, 11-, 11.20-, 15% for
Asian/Pacific Islander, Hispanic, Other/Unknown, and Native American respectively. We
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Figure 4.4: LOS with respect to patient’s age

also found that patient’s maximum of length of stay in the last 6 months, emergency admission status and past readmission history are significantly associated with the odds of
extended length of stay in ED. Along with being with such significant associations, they all
have an increase in odds of having a prolonged LOS ranging from approximately from 4%
to and 67% with maximum previous length of stay(last 6 months) and emergency admission
variables assuming respectively the smallest and largest increases in odds. In contrast, patient’s history of ED visits has a decrease in odds of causing a prolonged length of stay. The
Free-standing pediatric hospital variable appears to not be a significant factor to prolonged
LOS.
Certain diagnoses were significantly associated with prolonged LOS. These diagnoses include
Lymphoid leukemia (C91), Type 1 diabetes mellitus (E10), Suppurative and unspecified
otittis media(H66), Pneumonia, unspecified organism (J18), Disorders of newborn related
to short gestation and low birth weight, not elsewhere classified (P07), Family history of
certain disabilities and chronic diseases (leading to disablement) (Z82), Personal history of
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Figure 4.5: LOS with respect to race/ethnicity

other diseases and conditions (Z87), Pervasive developmental disorders (F84), and Sleep
disorders (G47). The decrease in odds associated with these conditions are greater than 18and less than 72%. On the other hand, the remaining conditions are risk factors that are
highly associated with extended length of stay with an increase of odds ranging from 3% to
445%. Variables with interaction(s)
An interaction arises if there is an eventual relationship among two or more variables. [101]
defines a statistical interaction as a scenario where the relation between a predictor and a
target variable depends on another independent variable, named as a moderator. Our mixed
effects model gives us a mathematical model that we can we use to estimate the probability
of a patient stay more than expected in the hospital given certain independent variables. For
example, suppose that we have three predictors, X, Z, and XZ. The model could roughly be
expressed as:
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log(

π
) = α0 + α1 X + α3 Z + α3 XZ
1−π

(4.1)

wherein α0 , α1 , α2 , α3 are the coefficients of the model. The statistical significance of the
interaction coefficient α3 informs about the association between X and the probability that
the outcome variable Y be equal to 1 depends on the predictor Z.
Table 4.8 and Table 4.9 show the results of two separate multivariate analyses. First, we
chose to discuss the results from the interaction effects between two main effects and the
remaining independent variables in the model: one for age of patient and the other one is for
the number of medications administered to a patient. In this process, we not only examine
the significance of the risk factor(s), but also the strength of the association. Then, the
odd ratios is calculated for each effect present in the model. As mentioned earlier, this is
conducted by deploying a mixed effects model.
Statistical interactions with age
Table 4.8 describes the main effects of age and those of the other existing independent variables. The results show that each main effect in the model is statistically and significantly (P
< 0.001) associated with prolonged LOS. Table 4.8 also shows that the interaction between
the factor age and any other factor is strongly associated with staying in ED more than 2
weeks. In addition, we notice that the main effects Age, Pervasive developmental disorders
(F84), Asthma (J45), Other disorders of urinary system (N39), Sleep disorders (G47), Convulsions, Not elsewhere classified (R56), and Obstructive and reflux uropathy (N13), with
negative coefficients are less likely to be important risk factors of prolonged length of stay.
This tells us that in the absence of statistical interactions with medical conditions a patient
is undergoing, older patients are less likely to have prolonged length of stay. In contrast,
without any interaction, patients that suffer from Streptococcus, Staphylococcus, and Enterococcus as the cause of diseases classified elsewhere (B95), Other anemias (D64), Major
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depressive disorder, single episode (F32), and Attention-deficit hyperactivity disorders (F90)
are more likely to stay longer in hospital in the case their condition worsens.
From the second part of Table 4.8, we can easily see that the interactions between age and
conditions such as Pervasive development disorders (F84), Asthma (J45), Certain disorders
of the urinary system(N39), Streptococcus, Staphylococcus, and Enterococcus diseases classified elsewhere (B95), Certain functional intestinal disorders (K59), and Sleep disorders
(G47) are statistically significant to the prolonged length of stay in hospital. In addition, we
can notice that these conditions interacting with age produce some positive effects on the
length of stay. This implies that patients that face the deterioration of their health, based
on the evolution of these conditions, are more likely to stay longer than expected in hospital.
For the sake of understanding the concept of 2-way statistical interaction between age and
diagnoses or medical conditions, let us consider some graphical representations. Do note that
age and diagnoses are a continuous variable and a dichotomous variable respectively. Thus,
the two-way interaction between age and a particular diagnosis fit separate regression lines
(on the log-odds scale) for the effects of age for the groups with and without the condition.
A positive/negative interaction effect reflects a higher/lower slope for the line depicting the
effect of age for the group with the condition compared to the group without. The intercepts
of the lines are functions of the main effects that in combination with the slopes can produce
different scenarios (non-parallel non-intersecting lines within the range of values of age with
various slopes or non-parallel intersecting lines within the range of values of age with various
slopes). These scenarios are displayed (on the probability scale).
Figure 4.6 displays the statistical 2-way interaction between age and 4 diagnoses with positive
effects. The plots in Figure 4.6 show the predicted probability of prolonged length of stay
with respect to patients’ age. In the top left plot, we observe that the directions of the
effects size of the age between the level of the diagnosis are opposite. Second, we notice the
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presence of a statistical interaction between age and the Pervasive development disorders
(F84). Such an interaction is sustained by the intersection point between the two graphs.
Third, we can deduce that younger patients that do not suffer from Pervasive development
disorders (F84) are more likely to have a prolonged length of stay than patients that do not
have such a condition. Fourth, we remark that older patients with this condition have longer
length of stay. The right top plot is about two non-parallel lines depicting the level of the
asthma diagnosis. Since the two lines are not parallel, we can say that they will certainly
intersect at a certain age greater than 17. As with the previous graph, we can see that the
direction of the effects size of the age among patients with asthma and those with no-asthma
are opposite. It results from this that older patients with asthma conditions have higher
chance to have a prolonged length of stay. The left bottom plot shows that patients with
certain disorders of the urinary system(N39) are more likely to have a longer length of stay
once they get older. The right bottom graph indicates that the interaction associated with
infections due to Streptococcus, staphylococcus, and enterococcus(B95) was insufficient to
change the trend imposed by the main effects of age even though the direction of the effect
size of the interaction term was positive.
Statistical interactions could also have negative effect sizes. The second part of Table 4.8
shows some examples where the coefficients of condition-age interaction are negative values.
Arranged in decreasing order of the magnitude, the involved conditions in our study that have
negative interaction effect sizes with age include Attention-deficit hyperactivity disorders
(F90), Major depressive disorder, single episode (F32), Obstructive and reflux uropathy
(N13), Convulsions, not elsewhere classified (R56), and Other anemias (D64). Figure 4.7
represents the plots of some statistical interactions(with negative interaction effect sizes)
between age and the top 4 conditions. In the top left graph, the predicted probability length
of stay is displayed in terms of the age of the patients. From this graph, we can see that
the direction of the effects size of the age among patients that suffer from attention-deficit
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hyperactivity disorders (F90) condition and those who do not have the so-called condition are
opposite. We can then notice an existing interaction between the two level of the attentiondeficit hyperactivity disorders (F90) condition. We can also notice that younger patients
with the attention-deficit hyperactivity disorders (F90) condition have higher probability of
having longer length of stay. A reverse scenario is seen with older patients. Similar findings
are displayed in the top right graph, with the exception that among the patients that do not
have the conditions, the predicted probability of longer LOS is much smaller in this case.
The bottom two graphs present the almost the same features in the direction of direction of
the effects size of the age among patients that suffer from Obstructive and reflux uropathy
(N13) and Convulsions, not elsewhere classified (R56). However, it should be highlighted
that patients with these two mental health conditions tend to have longer length of stays than
their peers. The graphs were interpolated cutting across ages younger than the minimum
age for diagnosis of these conditions. Obstructive and reflux uropathy (N13) and convulsions
(R56) had similar interactions with patients diagnosed with these conditions have reduced
odds for prolonged length of stay and further reduction in odds as patient age increases.
Statistical interactions with the number of medication administered during the
first 24 hours of hospitalization
Table 4.9 depicts the statistical interactions between the number of medications and the other
independent variables that are present in our model. It results from the first part of the table
that besides the factors Gastro-esophageal reflux disease (K21), Other functional intestinal
disorders (K59), Scoliosis (M41), Neonatal jaundice from other and unspecified causes (P59),
Transitory disorders of carbohydrate metabolism specific to newborn (P70), lack of expected
normal physiological development in childhood and adults (R62) and Personal risk factors,
not elsewhere classified (Z91), which accounts for of all the main effects in the model, the
remaining factors are significantly and statistically(P < 0.001) associated with prolonged
length of stay.
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The second part of Table 4.9 indicates the interaction effects between the number of medications and diagnoses. Strikingly, we found statistically significant interactions between the
number of medications and the factor diagnoses present in the study. Of these statistically
significant interactions, ∼ 20 percent have a negative interaction effect on the length of stay.
To better illustrate the effects of the 2-way statistical interactions between the number of
medications administered and different diagnoses, let us analyze the corresponding graphical representations. The scenarios are identical for the interaction between the number of
medicines that have been administered to the patients during the first 24 hours after admission and particular diagnoses. On the log-odds scale, the two-way interaction between the
number of medications and a diagnosis fits separate regression lines for the effects of number
of medications for the groups with and without the condition. A positive/negative interaction effect reflects a higher/lower slope for the line depicting the effect of age for patients
under medications compared to the ones without medications. As previously stated, the
intercepts of the lines are functions of the main effects that in combination with the slopes
can produce different scenarios (non-parallel non-intersecting lines within the range of values
of age with various slopes or non-parallel intersecting lines within the range of values of age
with various slopes). Figure 4.8, and Figure 4.9 depict these scenarios on the probability
scale.
For this, we consider 4 top (diagnoses Liveborn infants according to place of birth and type of
delivery (Z38), Disorders of newborn related to long gestation and high birth weight (P08),
Viral and other specified intestinal infections (A08), and Acute bronchiolitis (J21)) that have
positive interaction diagnoses with number of medication factor (Figure 4.8). In the top left
graph where the predicted probability length of stay is displayed in terms of the number
of administered medications. We notice that with respect to small number of medications
administered in the first 24 hours after admission, newborns and children of other ages (who
were not born during the index encounter) have almost the same odds of prolonged length
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of stay. Opposed to this, as the number of administered medications increases within 24
hours, the odds for newborns exponentially increases. We also see that after 25 administred
medications, the odds for longer length of stay remains the same among liveborns. This
is indicated by the existence of the plateau reached after 25 administered medications. A
similar but less pronounced effect is seen for disorders of newborns related to the remaining
top 3 diagnoses.
Lastly, in the context of negative interaction effects, we chose the top 4 diagnoses which are
congenital malformations of cardiac septa (Q21), scoliosis (M41), congenital malformations
of the great arteries (Q25), and essential primary hypertension (I10). Figure 4.9 gives the
graphical representations of the corresponding interactions with the number of administered
medical. First, we notice that for smaller number of medications administered within 24
hours, regardless of the age, the patients have the same likelihood for longer length of stay.
In addition, it is shown that the effects size of the number of administered with 24 hours
among liverborns and among patients of other ages is the same are in the same direction. It
is also found patients with these conditions have reduced odds of prolonged length of stay
but the odds increases as the number of medication increase
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Figure 4.6: Positive interaction effect sizes with age

Figure 4.7: Negative interaction effect sizes with agewith age
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Figure 4.8: Positive interaction effect sizes with number of medications

Figure 4.9: Negative interaction effect sizes with number of medications
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Machine Learning Consideration
The amenable meta-optimization task achieves certain parameters that can be assumed as
the best performing set of parameters. In the best case, we have a maximum tree depth of
8, learning rate of 0.3, gamma of 4, and minimum child weight of 0. A full description of
the involved parameters is given in Table 4.1.
Model Performance
As mixed effects model returns a probability, a classification threshold of value 0.068 was
set since the beginning of the study. A value greater or equal to 0.068 will indicates that a
specific patient is at high risk of having a prolonged length of stay, a value below indicates
that the patient is not at high risk of staying more than expected. At this threshold and in
the absence of interventions, of 4 patients that are flagged as being at high risks only one of
them would have a prolonged length of stay. With the set threshold, the mixed effects model
achieved an AUROC of 0.887 (0.885, 0.889), and at a specificity of 0.900, the sensitivity
positive, positive predictive value, F1 score, and NNE were 0.667, 0.264, 0.380 and 3.782
respectively. The area under the precision recall curve was 0.513.
On the other hand, we observed a much higher performance of the chosen machine learning
model. The AUROC obtained by the extreme gradient boost model was 0.931 (0.930, 0.933).
At a specificity 0.900, the other metrics including sensitivity, positive predictive value, F1
score, and NNE assumed 0.786, 0.294, 0.428, and 3.398. An interpretation of this obtained
NNE values indicates that at the set threshold, 2 in 7 patients flagged at high risk for
prolonged length of stay would indeed have a prolonged length of stay in the absence of
interventions. The are under the precision-recall curve was 0.611.
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4.3

Discussion

In this work, a retrospective study was conducted to identify all of the clinically vital factors
that are statistically and significantly associated with hospital length of stay. For this,
a mixed effects model was used to extensively analyze the factors as well as a machine
learning algorithm for prediction. In this stride, interesting findings were observed. Some of
the findings are in full agreement with what clinically cited as factors to hospital prolonged
length of stay, and others are newly discovered. Newborns and neonatal population tend to
have the longest length of stay. These patients typically stay longer than 2 weeks. This is
expected in the case of admissions to the NICU after birth and within the first 28 days of
life. This finding reinforces the idea that neonatal population has very distinctive needs and
clinical presentation than the rest of the pediatric population. The proportion of neonatal
children with prolonged length of stay is 0.087 and significantly greater than their older peers
with a rate of 0.040. This creates a strong case for follow-up studies with focus specifically
on the neonatal population to find risk factors peculiar to neonates of which interventions
for improved quality of care may be developed.
The next set of findings is related to pediatric infectious diseases, cerebral palsy, cardiovascular complications, neurological complications, and mental health conditions. We identified
an increased likelihood of prolonged length of stay in almost all cases of these diseases. But
the effect of mental health conditions is complicated by the age of the patient and the number
of medications administered (during the firs 24 hours of admission) as a proxy for severity
of overall illnesses. This indicates that conditions such as pneumonia, sepsis, cerebral palsy,
neurological conditions of the brain, abnormalities of heart beat, and complications after
surgery may be benefit from targeted interventions tailored to each condition. Interventions relating to mental health conditions such as pervasive development disorders, major
depressive disorder, and attention-deficit hyperactivity disorder should consider the age of
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the patients as the risk of prolonged length of stay is modified by the age of the patient. In
addition, mental health conditions such as conduct disorders (F91), and reaction to severe
stress, and adjustment disorders (F43) have risk modified by the overall severity of illness as
measured by the number of medications being administered to these patients.
Conditions affecting the respiratory or pulmonary system such as bacterial pneumonia,
acute bronchiolitis, acute upper respiratory infections of multiple and unspecified sites (J06),
asthma, and respiratory conditions such as pulmonary collapse, disease of bronchus, and disorders of the diaphragm may also be considered for targeted interventions aimed at reducing
the probability of unnecessarily prolonged length of stay.
A high model performance was achieved with the mixed effects model with statistics that indicate potential usefulness if implemented electronically with associated interventions. But
we considered the large number of statistical interactions discovered in the mixed effects
model. These interactions were discovered simply by considering all 2-way statistical interactions between diagnoses and both the age of the child and the number of medications
administered during the first 24 hours of hospitalization. This unusually high number of
interactions indicated that several other and potentially higher order interactions exist. We
explored this possibility bu considering deep extreme gradient boosting trees that explore
interactions in computationally feasible ways than can be achieved in equivalent regression
models. The resulting machine learning model obtained this way indicated that a statistically significant improvement in model performance was achieved due to the presence of
higher order interactions. In other words, the factors driving pediatric hospital length of
stay are complex. Unfortunately, unlike regression models, machine learning models do not
readily lend themselves to the statistical interpretation of the complexities modelled within
them. Even attempts at explanations are obtained by searching for linear approximations.
However, pooling all the major findings of this study indicate the need of studies on specific
pediatric subpopulations within which specialty-dependent complexities may be modelled
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using corresponding mixed effects regressions algorithms. These subpopulations should include the neonatal, mental, and pediatric chronic conditions. These studies are likely to
reveal additional insights on the phenomena affecting hospital length of stay that may be
helpful in the development of specialty-based intervention protocols.
There were several limitations of this study. The challenges of conducting research with
electronic medical records of patients besets this study. The data were not collected for
the purpose of research and as such may contain random errors attributable to data entry
and storage, as well as differences in the standard of care across organizations. The use
of diagnosis codes is particularly nuanced but it is the best data available. Limitations
around differences in hospital administration were considered, and their effects mitigated by
the choice of mixed effects model that treated hospitals as random intercepts with patients
nested within them. Lastly, the implementation of either or both of the statistical and
machine learning model would require the use of highly skilled statisticians or data scientists
as well as robust information technology team that may be able to integrate statistical
and machine learning model in the electronic health records. Notwithstanding, this study
identified subgroups within the pediatric population that may be targeted for improvement in
quality of care that could result in reduction of unnecessary prolongation of hospitalization.
Future studies focusing specifically on the neonatal population is highly encouraged. In
addition, studies on pediatric mental health and chronic conditions may result in additional
and novel discoveries.
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4.4

Summary

Prolonged length of stay (LOS) in medical facilities significantly increases the risk of healthcareassociated infections (HAI) in pediatric and adult patients, often disrupting the access to
healthcare and overall health outcomes as well as increasing the financial burden on the entire system. In this study, we designed and implemented a comprehensive study to identify
new clinical and demographic factors associated with prolonged length of stay (> 2 weeks)
among pediatric patients (aged 18 years and under) in a number of free-standing pediatric
and mixed medical facilities. For this, two approaches(univariate and multivariate) were
used to conduct statistical analyses. The univariate study helped us explore each variable
involved in the final data set, separately. The multivariate study was performed by building
a nested mixed effects model. This provided us with valid statistical inferences. The mixed
effects model accounts for the hierarchical structure of the data and assesses the statistical
significance and effect sizes of age, race/ethnicity, number of medications, medical family
history, presence of infection agents (fungi, bacteria,virus), cancer diagnoses and other conditions as well as demographic and clinical variables. Furthermore, a stochastic gradient
boosting model was built for prediction to present ways to improve the care quality for
patients at high risk of prolonged length of stay, and avoid unnecessary expenses.
Our model identified 11 main effect variables with significant effects on the odds of prolonged
length of stay, 12 two-way interaction between age and certain conditions and 33 two-way
interaction between the number of medications and certain conditions. The AUC for the
mixed effects model was 0.89 and the extreme gradient booster attained AUC of 0.93.
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Table 4.2: Summary Statistics LOS Pediatrics

Variables

LOS 1 week

LOS > 1

or less

week

n (%) or

n (%) or

mean (sd)

mean (sd)

Female

225492 (47.35)

11553 (45.90)

Male

250737 (52.65)

13618 (54.10)

Commercial

152772 (32.08)

6917 (27.48)

Governmental

184555 (38.75)

11777 (46.79)

Sex

Payer

p value

Levels
(chi-squared
or t-test)

< 0.001

(Medicare,

< 0.001

Medicaid)
18226 (3.83)

1001 (3.98)

Self-pay

10674 (2.24)

460 (1.83)

Other

110002 (23.10)

5016 (19.93)

AGE

5.93 (6.08)

4.56 (5.97)

Caucasian

255472 (53.64)

12860 (51.09)

Hispanic

17889 (3.76)

895 (3.56)

Black/African

106198 (22.30)

5489 (21.81)

Other
Governmental
(Champus, etc)

Age

< 0.001

< 0.001

Race/Ethnicity
American
Asian/Pacific

8702 (1.83)

427 (1.70)

Native American

6920 (1.45)

425 (1.69)

Other/Unknown

81048 (17.02)

5075 (20.16)

Previous ED visits

prevEDcat0

363531 (76.34)

21140 (83.99)

(last 6mo)

prevEDcat1

112698 (23.66)

4031 (16.01)

Islander

< 0.001
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Maximum previous
length of stay (last

-

1.52 (4.95)

4.33 (9.59)

< 0.001

Number Of Meds

2.23 (4.45)

11.16 (11.41)

< 0.001

Number Of

0.10 (0.51)

0.32 (1.01)

No

77436 (16.26)

3772 (14.99)

Yes

398793 (83.74)

21399 (85.01)

No

415569 (87.26)

19766 (78.53)

Yes

60660 (12.74)

5405 (21.47)

is Pediatric 0

236191 (49.60)

10269 (40.80)

is Pediatric 1

240038 (50.40)

14902 (59.20)

Viral and other

No

471186 (98.94)

25024 (99.42)

specified intestinal

Yes

5043 (1.06)

147 (0.58)

No

471695 (99.05)

24017 (95.42)

Yes

4534 (0.95)

1154 (4.58)

Viral infection of

No

470270 (98.75)

24789 (98.48)

unspecified site (B34)

Yes

5959 (1.25)

382 (1.52)

Streptococcus,

No

468183 (98.31)

23936 (95.09)

Staphylococcus, and

Yes

8046 (1.69)

1235 (4.91)

6mo)
Number of
medications
Number of
procedures
Procedure
< 0.001

Emergent Admission

Readmission History

< 0.001

Free. . .

< 0.001

< 0.001
infections (A08)
Other sepsis (A41)

< 0.001

< 0.001

< 0.001
Enterococcus as the cause
of diseases classified
elsewhere (B95)
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Other bacterial agents as

No

469698 (98.63)

23888 (94.90)

the cause of diseases

Yes

6531 (1.37)

1283 (5.10)

Viral agents as the cause

No

460317 (96.66)

24431 (97.06)

of diseases classified

Yes

15912 (3.34)

740 (2.94)

No

470587 (98.82)

24676 (98.03)

Yes

5642 (1.18)

495 (1.97)

No

467694 (98.21)

24964 (99.18)

Yes

8535 (1.79)

207 (0.82)

No

466525 (97.96)

23589 (93.71)

Yes

9704 (2.04)

1582 (6.29)

Purpura and other

No

471560 (99.02)

24293 (96.51)

hemorrhagic conditions

Yes

4669 (0.98)

878 (3.49)

No

470668 (98.83)

24190 (96.10)

Yes

5561 (1.17)

981 (3.90)

Other disorders of white

No

470868 (98.87)

24638 (97.88)

blood cells (D72)

Yes

5361 (1.13)

533 (2.12)

No

469772 (98.64)

25108 (99.75)

Yes

6457 (1.36)

63 (0.25)

No

469530 (98.59)

24848 (98.72)

Yes

6699 (1.41)

323 (1.28)

No

449670 (94.42)

24209 (96.18)

Yes

26559 (5.58)

962 (3.82)

Other disorders of fluid,

No

461167 (96.84)

21606 (85.84)

electrolyte and acid-base

Yes

15062 (3.16)

3565 (14.16)

< 0.001
classified elsewhere (B96)
< 0.001
elsewhere (B97)
Lymphoid leukemia (C91)

< 0.001

Sickle-cell disorders (D57)

< 0.001

Other anemias (D64)

< 0.001

< 0.001
(D69)
Neutropenia (D70)

< 0.001

<0.001

Type 1 diabetes mellitus (E10)

<0.001

Overweight and obesity (E66)

0.110

Volume depletion (E86)

< 0.001

< 0.001
balance (E87)
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Major depressive disorder,

No

467416 (98.15)

24435 (97.08)

single episode (F32)

Yes

8813 (1.85)

736 (2.92)

No

466936 (98.05)

24511 (97.38)

Yes

9293 (1.95)

660 (2.62)

Reaction to severe stress,

No

469188 (98.52)

24576 (97.64)

and adjustment disorders

Yes

7041 (1.48)

595 (2.36)

Pervasive developmental

No

471185 (98.94)

24882 (98.85)

disorders (F84)

Yes

5044 (1.06)

289 (1.15)

ther disorders of

No

471193 (98.94)

24736 (98.27)

psychological development

Yes

5036 (1.06)

435 (1.73)

Attention-deficit

No

464585 (97.55)

24456 (97.16)

hyperactivity disorders

Yes

11644 (2.45)

715 (2.84)

No

471128 (98.93)

24527 (97.44)

Yes

5101 (1.07)

644 (2.56)

Epilepsy and recurrent

No

458341 (96.24)

24071 (95.63)

seizures (G40)

Yes

17888 (3.76)

1100 (4.37)

No

467634 (98.20)

24355 (96.76)

Yes

8595 (1.80)

816 (3.24)

No

469797 (98.65)

24653 (97.94)

Yes

6432 (1.35)

518 (2.06)

No

468274 (98.33)

23958 (95.18)

Yes

7955 (1.67)

1213 (4.82)

< 0.001

Other anxiety disorders (F41)

< 0.001
< 0.001

(F43)
0.190

<0.001
(F88)
<0.001
(F90)
Conduct disorders (F91)

< 0.001

< 0.001

Sleep disorders (G47)

< 0.001

Cerebral palsy (G80)

< 0.001

Other disorders of brain (G93)

< 0.001
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Suppurative and unspecified

No

468492 (98.38)

25038 (99.47)

otitis media (H66)

Yes

7737 (1.62)

133 (0.53)

Essential (primary)

No

471850 (99.08)

24404 (96.95)

hypertension (I10)

Yes

4379 (0.92)

767 (3.05)

Other cardiac arrhythmias

No

471856 (99.08)

24354 (96.75)

(I49)

Yes

4373 (0.92)

817 (3.25)

Acute upper respiratory

No

463782 (97.39)

24827 (98.63)

infections of multiple and

Yes

12447 (2.61)

344 (1.37)

Bacterial pneumonia, not

No

470220 (98.74)

24465 (97.20)

elsewhere classified (J15)

Yes

6009 (1.26)

706 (2.80)

Pneumonia, unspecified

No

459014 (96.39)

24188 (96.09)

organism (J18)

Yes

17215 (3.61)

983 (3.91)

No

455023 (95.55)

24546 (97.52)

Yes

21206 (4.45)

625 (2.48)

No

432614 (90.84)

24200 (96.14)

Yes

43615 (9.16)

971 (3.86)

Acute respiratory distress

No

470722 (98.84)

24815 (98.59)

syndrome (J80)

Yes

5507 (1.16)

356 (1.41)

Respiratory failure, not

No

467134 (98.09)

22885 (90.92)

elsewhere classified (J96)

Yes

9095 (1.91)

2286 (9.08)

Other respiratory disorders

No

465501 (97.75)

23391 (92.93)

(J98)

Yes

10728 (2.25)

1780 (7.07)

Gastro-esophageal reflux

No

460106 (96.61)

23263 (92.42)

disease K21

Yes

16123 (3.39)

1908 (7.58)

No

468467 (98.37)

25016 (99.38)

Yes

7762 (1.63)

155 (0.62)

< 0.001

< 0.001

< 0.001

< 0.001
unspecified sites (J06)
< 0.001

0.017

Acute bronchiolitis (J21)

<0.001

Asthma (J45)

<0.001

<0.001

< 0.001

< 0.001

< 0.001

Acute appendicitis (K35)

< 0.001
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Other and unspecified

No

466229 (97.90)

24407 (96.96)

noninfective gastroenteritis

Yes

10000 (2.10)

764 (3.04)

Paralytic ileus and intestinal

No

471611 (99.03)

24491 (97.30)

obstruction without hernia

Yes

4618 (0.97)

680 (2.70)

Other functional intestinal

No

457981 (96.17)

23391 (92.93)

disorders (K59)

Yes

18248 (3.83)

1780 (7.07)

Cellulitis and acute

No

465002 (97.64)

24720 (98.21)

lymphangitis (L03)

Yes

11227 (2.36)

451 (1.79)

No

471283 (98.96)

24868 (98.80)

Yes

4946 (1.04)

303 (1.20)

Other and unspecified soft

No

471580 (99.02)

24875 (98.82)

tissue disorders, not

Yes

4649 (0.98)

296 (1.18)

Obstructive and reflux

No

470817 (98.86)

24689 (98.09)

uropathy (N13)

Yes

5412 (1.14)

482 (1.91)

Other disorders of urinary

No

468334 (98.34)

24484 (97.27)

system (N39)

Yes

7895 (1.66)

687 (2.73)

Disorders of newborn related

No

469040 (98.49)

20310 (80.69)

to short gestation and low

Yes

7189 (1.51)

4861 (19.31)

Disorders of newborn related

No

469849 (98.66)

24934 (99.06)

to long gestation and high

Yes

6380 (1.34)

237 (0.94)

No

471406 (98.99)

22051 (87.60)

< 0.001
and colitis (K52)
<0.001
(K56)
<0.001

<0.001

Scoliosis (M41)

0.013

0.002
elsewhere classified (M79)
< 0.001

< 0.001

< 0.001
birth weight, not elsewhere
classified (P07)
< 0.001
birth weight (P08)
Respiratory distress of

< 0.001
newborn (P22)
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Yes

4823 (1.01)

3120 (12.40)

Other respiratory conditions

No

470980 (98.90)

21584 (85.75)

originating in the perinatal

Yes

5249 (1.10)

3587 (14.25)

Cardiovascular disorders

No

471319 (98.97)

22500 (89.39)

originating in the perinatal

Yes

4910 (1.03)

2671 (10.61)

Neonatal jaundice from other

No

460905 (96.78)

21370 (84.90)

and unspecified causes (P59)

Yes

15324 (3.22)

3801 (15.10)

Transitory disorders of

No

472203 (99.15)

23975 (95.25)

carbohydrate metabolism

Yes

4026 (0.85)

1196 (4.75)

Feeding problems of newborn

No

471859 (99.08)

22596 (89.77)

(P92)

Yes

4370 (0.92)

2575 (10.23)

Other conditions originating

No

470078 (98.71)

23245 (92.35)

in the perinatal period (P96)

Yes

6151 (1.29)

1926 (7.65)

Congenital malformations of

No

467151 (98.09)

22430 (89.11)

cardiac septa (Q21)

Yes

9078 (1.91)

2741 (10.89)

Congenital malformations of

No

472180 (99.15)

23090 (91.73)

great arteries (Q25)

Yes

4049 (0.85)

2081 (8.27)

Abnormalities of heart beat

No

462313 (97.08)

23585 (93.70)

(R00)

Yes

13916 (2.92)

1586 (6.30)

No

469262 (98.54)

24923 (99.01)

Yes

6967 (1.46)

248 (0.99)

Abnormalities of breathing

No

446092 (93.67)

22427 (89.10)

(R06)

Yes

30137 (6.33)

2744 (10.90)

< 0.001
period (P28)
< 0.001
period (P29)
< 0.001

< 0.001
specific to newborn (P70)
< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

Cough (R05)

< 0.001

<0.001

88

Other symptoms and signs

No

454487 (95.43)

24095 (95.73)

involving the circulatory and

Yes

21742 (4.57)

1076 (4.27)

No

460785 (96.76)

24550 (97.53)

Yes

15444 (3.24)

621 (2.47)

No

454020 (95.34)

23773 (94.45)

Yes

22209 (4.66)

1398 (5.55)

Other symptoms and signs

No

467938 (98.26)

24396 (96.92)

involving the digestive

Yes

8291 (1.74)

775 (3.08)

Symptoms and signs

No

468191 (98.31)

24591 (97.70)

involving emotional state

Yes

8038 (1.69)

580 (2.30)

Fever of other and unknown

No

442745 (92.97)

23372 (92.85)

origin (R50)

Yes

33484 (7.03)

1799 (7.15)

No

470066 (98.71)

24819 (98.60)

Yes

6163 (1.29)

352 (1.40)

Convulsions, not elsewhere

No

462717 (97.16)

24526 (97.44)

classified (R56)

Yes

13512 (2.84)

645 (2.56)

Lack of expected normal

No

462776 (97.18)

23701 (94.16)

physiological development in

Yes

13453 (2.82)

1470 (5.84)

Symptoms and signs

No

462577 (97.13)

22677 (90.09)

concerning food and fluid

Yes

13652 (2.87)

2494 (9.91)

Findings of drugs and other

No

471642 (99.04)

24431 (97.06)

substances, not normally

Yes

4587 (0.96)

740 (2.94)

0.032
respiratory system (R09)
Abdominal and pelvic pain (R10)

<0.001

Nausea and vomiting (R11)

<0.001

<0.001
system and abdomen (R19)
<0.001
(R45)
0.491

Headache (R51)

0.163

0.011

< 0.001
childhood and adults (R62)
< 0.001
intake (R63)
< 0.001
found in blood (R78)
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Surgical operation and other

No

471665 (99.04)

24491 (97.30)

surgical procedures as the

Yes

4564 (0.96)

680 (2.70)

Place of occurrence of the

No

463240 (97.27)

24308 (96.57)

external cause (Y92)

Yes

12989 (2.73)

863 (3.43)

Encounter for observation

No

469243 (98.53)

23633 (93.89)

and evaluation of newborn

Yes

6986 (1.47)

1538 (6.11)

Encounter for immunization

No

459579 (96.50)

23633 (93.89)

(Z23)

Yes

16650 (3.50)

1538 (6.11)

No

468046 (98.28)

25032 (99.45)

Yes

8183 (1.72)

139 (0.55)

Liveborn infants according to

No

418130 (87.80)

22153 (88.01)

place of birth and type of

Yes

58099 (12.20)

3018 (11.99)

Encounter for other aftercare

No

462358 (97.09)

23759 (94.39)

and medical care (Z51)

Yes

13871 (2.91)

1412 (5.61)

Persons encountering health

No

470703 (98.84)

24641 (97.89)

services for other counseling

Yes

5526 (1.16)

530 (2.11)

< 0.001
cause of abnormal reaction of
the patient, or of later
complication, without
mention of misadventure at
the time of the procedure
(Y83)
< 0.001

<0.001
for suspected diseases and
conditions ruled out (Z05)
<0.001

Outcome of delivery (Z37)

<0.001

0.326
delivery (Z38)
<0.001

<0.001
and medical advice, not
elsewhere classified (Z71)
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Long term (current) drug

No

468219 (98.32)

24619 (97.81)

therapy (Z79)

Yes

8010 (1.68)

552 (2.19)

Family history of certain

No

467499 (98.17)

24836 (98.67)

disabilities and chronic

Yes

8730 (1.83)

335 (1.33)

Family history of other

No

470836 (98.87)

24896 (98.91)

specific disorders (Z83)

Yes

5393 (1.13)

275 (1.09)

Personal history of certain

No

470511 (98.80)

24675 (98.03)

other diseases (Z86)

Yes

5718 (1.20)

496 (1.97)

Personal history of other

No

466394 (97.93)

24455 (97.16)

diseases and conditions (Z87)

Yes

9835 (2.07)

716 (2.84)

Personal risk factors, not

No

464485 (97.53)

24473 (97.23)

elsewhere classified (Z91)

Yes

11744 (2.47)

698 (2.77)

Artificial opening status

No

465233 (97.69)

23840 (94.71)

(Z93)

Yes

10996 (2.31)

1331 (5.29)

Other postprocedural states

No

466131 (97.88)

24328 (96.65)

(Z98)

Yes

10098 (2.12)

843 (3.35)

<0.001

<0.001
diseases (leading to
disablement) (Z82)
0.580

<0.001

<0.001

0.002

<0.001

<0.001
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Table 4.3: Results of the multivariate statistical analysis

Variable

Levels

Odds ratio

p value

Female

Reference

< 0.001

Male

0.943 (0.914,

Sex
0.973)

Payer

Commercial

Reference

Governmental

1.347 (1.293,

(Medicare,

1.404)

< 0.001

Medicaid)
Other Governmental

1.212 (1.114,

(Champus, etc)

1.319)

Self-pay

1.296 (1.157,
1.452)

Other

1.343 (1.275,
1.413)

Caucasian

Reference

Hispanic

1.106 (1.014,

0.023

1.207)
Race/Ethnicity
Black/African

1.140 (1.091,

American

1.191)

Asian/Pacific

1.004 (0.893,

Islander

1.129)

Native American

1.145 (0.995,

< 0.001

0.947

0.059

1.317)
Other/Unknown

1.112 (1.061,
1.166)

92

< 0.001

Previous ED visits (last 6mo)

-

0.621 (0.595, 0.649)

< 0.001

Maximum previous length of stay (last

-

1.042 (1.040, 1.044)

< 0.001

Free-standing pediatric hospital

Yes

1.431 (0.659, 3.107)

0.364

EmergentAdmission

Yes

1.672 (1.598, 1.749)

< 0.001

ReadmissionHistory

Yes

1.179 (1.124, 1.236)

< 0.001

Other sepsis (A41)

Yes

1.599 (1.449, 1.764)

< 0.001

Other bacterial agents as the cause of

Yes

1.912 (1.740, 2.100)

< 0.001

Lymphoid leukemia (C91)

Yes

0.562 (0.494, 0.640)

< 0.001

Type 1 diabetes mellitus (E10)

Yes

0.279 (0.211, 0.369)

< 0.001

Cerebral palsy (G80)

Yes

1.314 (1.156, 1.494)

< 0.001

Other disorders of brain (G93)

Yes

1.224 (1.119, 1.340)

< 0.001

Suppurative and unspecified otitis me-

Yes

0.522 (0.422, 0.645)

< 0.001

Yes

1.867 (1.664, 2.094)

< 0.001

organism

Yes

0.796 (0.727, 0.872)

< 0.001

Disorders of newborn related to short

Yes

5.466 (5.084, 5.877)

< 0.001

Respiratory distress of newborn (P22)

Yes

1.839 (1.687, 2.004)

< 0.001

Other respiratory conditions originat-

Yes

2.579 (2.368, 2.810)

< 0.001

Yes

1.184 (1.071, 1.309)

< 0.001

6mo)

diseases classified elsewhere (B96)

dia (H66)
Bacterial pneumonia, not elsewhere
classified (J15)
Pneumonia,

unspecified

(J18)

gestation and low birth weight, not
elsewhere classified (P07)

ing in the perinatal period (P28)
Cardiovascular disorders originating in
the perinatal period (P29)
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Other conditions originating in the

Yes

2.412 (2.180, 2.668)

< 0.001

Abnormalities of heart beat (R00)

Yes

1.106 (1.024, 1.195)

0.010

Symptoms and signs concerning food

Yes

1.630 (1.525, 1.742)

< 0.001

Yes

1.227 (1.091, 1.380)

< 0.001

Yes

1.239 (1.126, 1.363)

< 0.001

Encounter for immunization (Z23)

Yes

1.133 (1.029, 1.248)

0.011

Family history of certain disabilities

Yes

0.641 (0.551, 0.745)

< 0.001

Yes

0.816 (0.734, 0.907)

< 0.001

Other postprocedural states (Z98)

Yes

0.698 (0.632, 0.770)

< 0.001

Pervasive

Yes

0.577 (0.373, 0.893)

0.013

Sleep disorders (G47)

Yes

0.989 (0.842, 1.162)

0.891

Other functional intestinal disorders

Yes

1.028 (0.895, 1.181)

0.699

Yes

1.354 (1.157, 1.585)

< 0.001

perinatal period (P96)

and fluid intake (R63)
Surgical operation and other surgical
procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure (Y83)
Encounter for observation and evaluation of newborn for suspected diseases
and conditions ruled out (Z05)

and chronic diseases (leading to disablement) (Z82)
Personal history of other diseases and
conditions (Z87)

developmental

disorders

(F84)

(K59)
Reaction to severe stress, and adjustment disorders (F43)
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Streptococcus, Staphylococcus, and

Yes

1.031 (1.017, 1.046)

< 0.001

Yes

0.965 (0.953, 0.978)

< 0.001

single

Yes

0.946 (0.918, 0.976)

< 0.001

disorders

Yes

1.063 (1.026, 1.102)

< 0.001

Attention-deficit hyperactivity disor-

Yes

0.934 (0.909, 0.960)

< 0.001

Sleep disorders (G47)

Yes

1.031 (1.014, 1.047)

< 0.001

Asthma (J45)

Yes

1.052 (1.036, 1.068)

< 0.001

Other functional intestinal disorders

Yes

1.032 (1.020, 1.044)

< 0.001

Obstructive and reflux uropathy (N13)

Yes

0.947 (0.921, 0.974)

< 0.001

Other disorders of urinary system

Yes

1.034 (1.016, 1.052)

< 0.001

Yes

0.956 (0.936, 0.977)

< 0.001

Yes

0.904 (0.873, 0.935)

< 0.001

Present

1.096 (1.064, 1.128)

< 0.001

Present

1.044 (1.031, 1.058)

< 0.001

Sickle-cell disorders (D57)

Present

1.042 (1.023, 1.062)

< 0.001

Neutropenia (D70)

Present

1.035 (1.023, 1.047)

< 0.001

Volume depletion (E86)

Present

1.048 (1.038, 1.058)

< 0.001

Enterococcus as the cause of diseases
classified elsewhere (B95)
Other anemias (D64)
Major

depressive

disorder,

episode (F32)
Pervasive

developmental

(F84)

ders (F90)

(K59)

(N39)
Convulsions, not elsewhere classified
(R56)
Outcome of delivery (Z37)
Viral and other specified intestinal infections (A08)
Viral agents as the cause of diseases
classified elsewhere (B97)
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Other disorders of fluid, electrolyte and

Present

0.980 (0.975, 0.986)

< 0.001

Present

1.032 (1.018, 1.047)

< 0.001

Conduct disorders (F91)

Present

1.066 (1.044, 1.089)

< 0.001

Epilepsy and recurrent seizures (G40)

Present

1.026 (1.017, 1.035)

< 0.001

Essential (primary) hypertension (I10)

Present

0.969 (0.959, 0.978)

< 0.001

Acute upper respiratory infections of

Present

1.047 (1.029, 1.065)

< 0.001

Acute bronchiolitis (J21)

Present

1.086 (1.071, 1.101)

< 0.001

Asthma (J45)

Present

1.026 (1.017, 1.034)

< 0.001

Respiratory failure, not elsewhere clas-

Present

0.977 (0.970, 0.983)

< 0.001

Other respiratory disorders (J98)

Present

0.986 (0.979, 0.994)

< 0.001

Gastro-esophageal reflux disease (K21)

Present

1.025 (1.016, 1.033)

< 0.001

Acute appendicitis (K35)

Present

1.076 (1.052, 1.100)

< 0.001

Other functional intestinal disorders

Present

0.987 (0.980, 0.994)

< 0.001

Cellulitis and acute lymphangitis (L03)

Present

1.065 (1.050, 1.080)

< 0.001

Scoliosis (M41)

Present

0.964 (0.951, 0.976)

< 0.001

Disorders of newborn related to long

Present

1.124 (1.080, 1.169)

< 0.001

Present

1.049 (1.035, 1.063)

< 0.001

Present

1.044 (1.022, 1.067)

< 0.001

Present

1.076 (1.059, 1.093)

< 0.001

acid-base balance (E87)
Reaction to severe stress, and adjustment disorders (F43)

multiple and unspecified sites (J06)

sified (J96)

(K59)

gestation and high birth weight (P08)
Neonatal jaundice from other and unspecified causes (P59)
Transitory disorders of carbohydrate
metabolism specific to newborn (P70)
Feeding problems of newborn (P92)
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Congenital malformations of cardiac

Present

0.955 (0.949, 0.962)

< 0.001

Present

0.965 (0.957, 0.974)

< 0.001

Abnormalities of breathing (R06)

Present

1.043 (1.036, 1.051)

< 0.001

Other symptoms and signs involving

Present

1.022 (1.013, 1.032)

< 0.001

Abdominal and pelvic pain (R10)

Present

1.035 (1.023, 1.047)

< 0.001

Nausea and vomiting (R11)

Present

1.028 (1.019, 1.036)

< 0.001

Symptoms and signs involving emo-

Present

1.052 (1.035, 1.069)

< 0.001

Present

1.036 (1.028, 1.043)

< 0.001

Present

1.053 (1.041, 1.065)

< 0.001

Present

1.023 (1.015, 1.032)

< 0.001

Present

1.034 (1.023, 1.044)

< 0.001

Outcome of delivery (Z37)

Present

1.047 (1.019, 1.076)

< 0.001

Liveborn infants according to place of

Present

1.369 (1.342, 1.395)

< 0.001

Present

1.048 (1.039, 1.057)

< 0.001

septa (Q21)
Congenital malformations of great arteries (Q25)

the circulatory and respiratory system
(R09)

tional state (R45)
Fever of other and unknown origin
(R50)
Convulsions, not elsewhere classified
(R56)
Lack of expected normal physiological
development in childhood and adults
(R62)
Place of occurrence of the external
cause (Y92)

birth and type of delivery (Z38)
Encounter for other aftercare and medical care (Z51)
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Personal risk factors, not elsewhere

Present

1.024 (1.012, 1.036)

< 0.001

Present

1.024 (1.014, 1.033)

< 0.001

classified (Z91)
Artificial opening status (Z93)

Table 4.5: Summary Statistics LOS Pediatrics

Variables

LOS 1 week

LOS > 1

or less

week

n (%) or

n (%) or

mean (sd)

mean (sd)

225492

11553 (45.90)

p value

Levels

Female
Sex

(chisquared
or t-test)
< 0.001

(47.35)
Male

250737

13618 (54.10)

(52.65)
Commercial

152772

6917 (27.48)

(32.08)
Payer

Governmental

184555

(Medicare,

(38.75)

11777 (46.79)

< 0.001

Medicaid)
Other

18226 (3.83)

1001 (3.98)

Self-pay

10674 (2.24)

460 (1.83)

Other

110002

5016 (19.93)

Governmental
(Champus, etc)

(23.10)
Age

AGE

98

5.93 (6.08)

4.56 (5.97)

< 0.001

Caucasian

255472

12860 (51.09)

(53.64)
Hispanic

17889 (3.76)

895 (3.56)

Black/African

106198

5489 (21.81)

American

(22.30)

Asian/Pacific

8702 (1.83)

427 (1.70)

Native American

6920 (1.45)

425 (1.69)

Other/Unknown

81048 (17.02)

5075 (20.16)

prevEDcat0

363531

21140 (83.99)

Race/Ethnicity

< 0.001

Islander

Previous ED visits (last

< 0.001
6mo)

(76.34)
prevEDcat1

112698

4031 (16.01)

(23.66)
Maximum

previous

-

1.52 (4.95)

4.33 (9.59)

< 0.001

Number Of Meds

2.23 (4.45)

11.16 (11.41)

< 0.001

Number Of

0.10 (0.51)

0.32 (1.01)

No

77436 (16.26)

3772 (14.99)

Yes

398793

21399 (85.01)

length of stay (last 6mo)
Number of medications
Number of procedures

Procedure
Emergent Admission

< 0.001
(83.74)
No

415569

19766 (78.53)

Readmission History

< 0.001
(87.26)
Yes

60660 (12.74)

5405 (21.47)

is Pediatric 0

236191

10269 (40.80)

Free. . .

< 0.001
(49.60)

99

is Pediatric 1

240038

14902 (59.20)

(50.40)
Viral and other specified

No

471186

25024 (99.42)
< 0.001

intestinal infections (A08)

(98.94)
Yes

5043 (1.06)

147 (0.58)

No

471695

24017 (95.42)

Other sepsis (A41)

< 0.001
(99.05)

Viral infection of

Yes

4534 (0.95)

1154 (4.58)

No

470270

24789 (98.48)
< 0.001

unspecified site (B34)

Streptococcus,

(98.75)
Yes

5959 (1.25)

382 (1.52)

No

468183

23936 (95.09)
< 0.001

(98.31)

Staphylococcus, and
Enterococcus as the cause of

Yes

8046 (1.69)

1235 (4.91)

No

469698

23888 (94.90)

diseases classified elsewhere
(B95)
Other bacterial agents as the

< 0.001
(98.63)

cause of diseases classified
elsewhere (B96)

Yes

6531 (1.37)

1283 (5.10)

Viral agents as the cause of

No

460317

24431 (97.06)
< 0.001

diseases classified elsewhere
(B97)

(96.66)
Yes

15912 (3.34)

740 (2.94)

No

470587

24676 (98.03)

Lymphoid leukemia (C91)

< 0.001
(98.82)
Yes

5642 (1.18)

495 (1.97)

No

467694

24964 (99.18)

Sickle-cell disorders (D57)

< 0.001
(98.21)

100

Yes

8535 (1.79)

207 (0.82)

No

466525

23589 (93.71)

Other anemias (D64)

< 0.001
(97.96)

Purpura and other

Yes

9704 (2.04)

1582 (6.29)

No

471560

24293 (96.51)
< 0.001

hemorrhagic conditions (D69)

(99.02)
Yes

4669 (0.98)

878 (3.49)

No

470668

24190 (96.10)

Neutropenia (D70)

< 0.001
(98.83)

Other disorders of white

Yes

5561 (1.17)

981 (3.90)

No

470868

24638 (97.88)
<0.001

blood cells (D72)

(98.87)
Yes

5361 (1.13)

533 (2.12)

No

469772

25108 (99.75)

Type 1 diabetes mellitus (E10)

<0.001
(98.64)
Yes

6457 (1.36)

63 (0.25)

No

469530

24848 (98.72)

Overweight and obesity (E66)

0.110
(98.59)
Yes

6699 (1.41)

323 (1.28)

No

449670

24209 (96.18)

Volume depletion (E86)

< 0.001
(94.42)

Other disorders of fluid,

Yes

26559 (5.58)

962 (3.82)

No

461167

21606 (85.84)
< 0.001

electrolyte and acid-base

(96.84)

balance (E87)

Yes

15062 (3.16)

3565 (14.16)

Major depressive disorder,

No

467416

24435 (97.08)
< 0.001

single episode (F32)

(98.15)

101

Yes

8813 (1.85)

736 (2.92)

No

466936

24511 (97.38)

Other anxiety disorders (F41)

< 0.001
(98.05)

Reaction to severe stress, and

Yes

9293 (1.95)

660 (2.62)

No

469188

24576 (97.64)

adjustment disorders (F43)

Pervasive developmental

< 0.001

(98.52)
Yes

7041 (1.48)

595 (2.36)

No

471185

24882 (98.85)
0.190

disorders (F84)

ther disorders of

(98.94)
Yes

5044 (1.06)

289 (1.15)

No

471193

24736 (98.27)
<0.001

(98.94)

psychological development
(F88)

Yes

5036 (1.06)

435 (1.73)

Attention-deficit

No

464585

24456 (97.16)
<0.001

hyperactivity disorders (F90)

(97.55)
Yes

11644 (2.45)

715 (2.84)

No

471128

24527 (97.44)

Conduct disorders (F91)

< 0.001
(98.93)

Epilepsy and recurrent

Yes

5101 (1.07)

644 (2.56)

No

458341

24071 (95.63)
< 0.001

seizures (G40)

(96.24)
Yes

17888 (3.76)

1100 (4.37)

No

467634

24355 (96.76)

Sleep disorders (G47)

< 0.001
(98.20)
Yes

8595 (1.80)

816 (3.24)

No

469797

24653 (97.94)

Cerebral palsy (G80)

< 0.001
(98.65)

102

Yes

6432 (1.35)

518 (2.06)

No

468274

23958 (95.18)

Other disorders of brain (G93)

< 0.001
(98.33)

Suppurative and unspecified

Yes

7955 (1.67)

1213 (4.82)

No

468492

25038 (99.47)
< 0.001

otitis media (H66)

Essential (primary)

(98.38)
Yes

7737 (1.62)

133 (0.53)

No

471850

24404 (96.95)
< 0.001

hypertension (I10)

Other cardiac arrhythmias

(99.08)
Yes

4379 (0.92)

767 (3.05)

No

471856

24354 (96.75)
< 0.001

(I49)

Acute upper respiratory

(99.08)
Yes

4373 (0.92)

817 (3.25)

No

463782

24827 (98.63)
< 0.001

infections of multiple and

(97.39)

unspecified sites (J06)

Yes

12447 (2.61)

344 (1.37)

Bacterial pneumonia, not

No

470220

24465 (97.20)
< 0.001

elsewhere classified (J15)

Pneumonia, unspecified

(98.74)
Yes

6009 (1.26)

706 (2.80)

No

459014

24188 (96.09)
0.017

organism (J18)

(96.39)
Yes

17215 (3.61)

983 (3.91)

No

455023

24546 (97.52)

Acute bronchiolitis (J21)

<0.001
(95.55)
Yes

21206 (4.45)

625 (2.48)

No

432614

24200 (96.14)

Asthma (J45)

<0.001
(90.84)

103

Acute respiratory distress

Yes

43615 (9.16)

971 (3.86)

No

470722

24815 (98.59)
<0.001

syndrome (J80)

Respiratory failure, not

(98.84)
Yes

5507 (1.16)

356 (1.41)

No

467134

22885 (90.92)
< 0.001

elsewhere classified (J96)

Other respiratory disorders

(98.09)
Yes

9095 (1.91)

2286 (9.08)

No

465501

23391 (92.93)
< 0.001

(J98)

Gastro-esophageal reflux

(97.75)
Yes

10728 (2.25)

1780 (7.07)

No

460106

23263 (92.42)
< 0.001

disease K21

(96.61)
Yes

16123 (3.39)

1908 (7.58)

No

468467

25016 (99.38)

Acute appendicitis (K35)

< 0.001
(98.37)

Other and unspecified

Yes

7762 (1.63)

155 (0.62)

No

466229

24407 (96.96)
< 0.001

(97.90)

noninfective gastroenteritis
and colitis (K52)

Yes

10000 (2.10)

764 (3.04)

Paralytic ileus and intestinal

No

471611

24491 (97.30)
<0.001

obstruction without hernia

(99.03)

(K56)

Yes

4618 (0.97)

680 (2.70)

Other functional intestinal

No

457981

23391 (92.93)
<0.001

disorders (K59)

Cellulitis and acute

(96.17)
Yes

18248 (3.83)

1780 (7.07)

No

465002

24720 (98.21)
<0.001

lymphangitis (L03)

(97.64)

104

Yes

11227 (2.36)

451 (1.79)

No

471283

24868 (98.80)

Scoliosis (M41)

0.013
(98.96)

Other and unspecified soft

Yes

4946 (1.04)

303 (1.20)

No

471580

24875 (98.82)
0.002

tissue disorders, not

(99.02)

elsewhere classified (M79)

Yes

4649 (0.98)

296 (1.18)

Obstructive and reflux

No

470817

24689 (98.09)
< 0.001

uropathy (N13)

Other disorders of urinary

(98.86)
Yes

5412 (1.14)

482 (1.91)

No

468334

24484 (97.27)
< 0.001

system (N39)

Disorders of newborn related

(98.34)
Yes

7895 (1.66)

687 (2.73)

No

469040

20310 (80.69)

(98.49)

to short gestation and low
birth weight, not elsewhere

< 0.001

Yes

7189 (1.51)

4861 (19.31)

No

469849

24934 (99.06)

classified (P07)
Disorders of newborn related

< 0.001
to long gestation and high

(98.66)

birth weight (P08)

Yes

6380 (1.34)

237 (0.94)

Respiratory distress of

No

471406

22051 (87.60)
< 0.001

newborn (P22)

Other respiratory conditions

(98.99)
Yes

4823 (1.01)

3120 (12.40)

No

470980

21584 (85.75)
< 0.001

originating in the perinatal
period (P28)

(98.90)
Yes

105

5249 (1.10)

3587 (14.25)

Cardiovascular disorders

No

471319

22500 (89.39)
< 0.001

originating in the perinatal

(98.97)

period (P29)

Yes

4910 (1.03)

2671 (10.61)

Neonatal jaundice from other

No

460905

21370 (84.90)
< 0.001

and unspecified causes (P59)

Transitory disorders of

(96.78)
Yes

15324 (3.22)

3801 (15.10)

No

472203

23975 (95.25)
< 0.001

carbohydrate metabolism

(99.15)

specific to newborn (P70)

Yes

4026 (0.85)

1196 (4.75)

Feeding problems of newborn

No

471859

22596 (89.77)
< 0.001

(P92)

Other conditions originating

(99.08)
Yes

4370 (0.92)

2575 (10.23)

No

470078

23245 (92.35)
< 0.001

in the perinatal period (P96)

Congenital malformations of

(98.71)
Yes

6151 (1.29)

1926 (7.65)

No

467151

22430 (89.11)
< 0.001

cardiac septa (Q21)

Congenital malformations of

(98.09)
Yes

9078 (1.91)

2741 (10.89)

No

472180

23090 (91.73)
< 0.001

great arteries (Q25)

(99.15)
Yes

4049 (0.85)

2081 (8.27)

No

462313

23585 (93.70)

Abnormalities of heart beat (R00)

< 0.001
(97.08)
Yes

13916 (2.92)

1586 (6.30)

No

469262

24923 (99.01)

Cough (R05)

< 0.001
(98.54)
Yes

106

6967 (1.46)

248 (0.99)

No

446092

22427 (89.10)

Abnormalities of breathing (R06)

<0.001
(93.67)

Other symptoms and signs

Yes

30137 (6.33)

2744 (10.90)

No

454487

24095 (95.73)

involving the circulatory and
respiratory system (R09)

0.032

(95.43)
Yes

21742 (4.57)

1076 (4.27)

No

460785

24550 (97.53)

Abdominal and pelvic pain (R10)

<0.001
(96.76)
Yes

15444 (3.24)

621 (2.47)

No

454020

23773 (94.45)

Nausea and vomiting (R11)

<0.001
(95.34)

Other symptoms and signs

Yes

22209 (4.66)

1398 (5.55)

No

467938

24396 (96.92)
<0.001

(98.26)

involving the digestive
system and abdomen (R19)

Yes

8291 (1.74)

775 (3.08)

Symptoms and signs

No

468191

24591 (97.70)
<0.001

involving emotional state

(98.31)

(R45)

Yes

8038 (1.69)

580 (2.30)

Fever of other and unknown

No

442745

23372 (92.85)
0.491

origin (R50)

(92.97)
Yes

33484 (7.03)

1799 (7.15)

No

470066

24819 (98.60)

Headache (R51)

0.163
(98.71)

Convulsions, not elsewhere

Yes

6163 (1.29)

352 (1.40)

No

462717

24526 (97.44)
0.011

classified (R56)

(97.16)
Yes

107

13512 (2.84)

645 (2.56)

Lack of expected normal

No

462776

23701 (94.16)
< 0.001

physiological development in

(97.18)

childhood and adults (R62)

Yes

13453 (2.82)

1470 (5.84)

Symptoms and signs

No

462577

22677 (90.09)
< 0.001

concerning food and fluid

(97.13)

intake (R63)

Yes

13652 (2.87)

2494 (9.91)

Findings of drugs and other

No

471642

24431 (97.06)
< 0.001

substances, not normally

(99.04)

found in blood (R78)

Yes

4587 (0.96)

740 (2.94)

Surgical operation and other

No

471665

24491 (97.30)

(99.04)

surgical procedures as the

< 0.001
cause of abnormal reaction of

Yes

4564 (0.96)

680 (2.70)

No

463240

24308 (96.57)

the patient, or of later
complication, without
mention of misadventure at
the time of the procedure
(Y83)
Place of occurrence of the

< 0.001
external cause (Y92)

Encounter for observation

(97.27)
Yes

12989 (2.73)

863 (3.43)

No

469243

23633 (93.89)

and evaluation of newborn
for suspected diseases and

(98.53)

<0.001

Yes

6986 (1.47)

1538 (6.11)

No

459579

23633 (93.89)

conditions ruled out (Z05)
Encounter for immunization

<0.001
(Z23)

(96.50)
Yes

108

16650 (3.50)

1538 (6.11)

No

468046

25032 (99.45)

Outcome of delivery (Z37)

<0.001
(98.28)

Liveborn infants according to

Yes

8183 (1.72)

139 (0.55)

No

418130

22153 (88.01)
0.326

place of birth and type of

(87.80)

delivery (Z38)

Yes

58099 (12.20)

3018 (11.99)

Encounter for other aftercare

No

462358

23759 (94.39)
<0.001

and medical care (Z51)

Persons encountering health

(97.09)
Yes

13871 (2.91)

1412 (5.61)

No

470703

24641 (97.89)

(98.84)

services for other counseling
and medical advice, not

<0.001

Yes

5526 (1.16)

530 (2.11)

No

468219

24619 (97.81)

elsewhere classified (Z71)
Long term (current) drug

<0.001
therapy (Z79)

Family history of certain

(98.32)
Yes

8010 (1.68)

552 (2.19)

No

467499

24836 (98.67)

(98.17)

disabilities and chronic
diseases (leading to

<0.001

Yes

8730 (1.83)

335 (1.33)

No

470836

24896 (98.91)

disablement) (Z82)
Family history of other

0.580
specific disorders (Z83)

Personal history of certain

(98.87)
Yes

5393 (1.13)

275 (1.09)

No

470511

24675 (98.03)
<0.001

other diseases (Z86)

(98.80)
Yes

109

5718 (1.20)

496 (1.97)

Personal history of other

No

466394

24455 (97.16)
<0.001

diseases and conditions (Z87)

Personal risk factors, not

(97.93)
Yes

9835 (2.07)

716 (2.84)

No

464485

24473 (97.23)
0.002

elsewhere classified (Z91)

Artificial opening status

(97.53)
Yes

11744 (2.47)

698 (2.77)

No

465233

23840 (94.71)
<0.001

(Z93)

Other

(97.69)

postprocedural

Yes

10996 (2.31)

1331 (5.29)

No

466131

24328 (96.65)
<0.001

states (Z98)

(97.88)
Yes

110

10098 (2.12)

843 (3.35)

Table 4.6: Results of the multivariate statistical analysis

Variable

Levels

Odds ratio

p value

Female

Reference

< 0.001

Male

0.943 (0.914,

Sex
0.973)

Payer

Commercial

Reference

Governmental

1.347 (1.293,

(Medicare,

1.404)

< 0.001

Medicaid)
Other Governmental

1.212 (1.114,

(Champus, etc)

1.319)

Self-pay

1.296 (1.157,
1.452)

Other

1.343 (1.275,
1.413)

Caucasian

Reference

Hispanic

1.106 (1.014,

0.023

1.207)
Race/Ethnicity
Black/African

1.140 (1.091,

American

1.191)

Asian/Pacific

1.004 (0.893,

Islander

1.129)

Native American

1.145 (0.995,

< 0.001

0.947

0.059

1.317)
Other/Unknown

1.112 (1.061,
1.166)

111

< 0.001

Previous ED visits (last 6mo)

-

0.621 (0.595,

< 0.001

0.649)
Maximum previous length of stay

-

(last 6mo)

1.042 (1.040,

< 0.001

1.044)

Free-standing pediatric hospital

Yes

1.431 (0.659,

0.364

3.107)
EmergentAdmission

Yes

1.672 (1.598,

< 0.001

1.749)
ReadmissionHistory

Yes

1.179 (1.124,

< 0.001

1.236)
Other sepsis (A41)

Yes

1.599 (1.449,

< 0.001

1.764)
Yes

Other bacterial agents as the

1.912 (1.740,

< 0.001

2.100)

cause of diseases classified elsewhere (B96)
Lymphoid leukemia (C91)

Yes

0.562 (0.494,

< 0.001

0.640)
Type 1 diabetes mellitus (E10)

Yes

0.279 (0.211,

< 0.001

0.369)
Cerebral palsy (G80)

Yes

1.314 (1.156,

< 0.001

1.494)
Other disorders of brain (G93)

Yes

1.224 (1.119,

< 0.001

1.340)
Suppurative and unspecified oti-

Yes

tis media (H66)

0.522 (0.422,

< 0.001

0.645)

Bacterial pneumonia, not else-

Yes

where classified (J15)

1.867 (1.664,
2.094)

112

< 0.001

Pneumonia, unspecified organ-

Yes

ism (J18)

0.796 (0.727,

< 0.001

0.872)
Yes

Disorders of newborn related to

5.466 (5.084,

< 0.001

5.877)

short gestation and low birth
weight, not elsewhere classified
(P07)
Respiratory distress of newborn

Yes

(P22)
Other

1.839 (1.687,

< 0.001

2.004)
respiratory

originating

in

Yes

conditions

the

2.579 (2.368,

< 0.001

2.810)

perinatal

period (P28)
Cardiovascular disorders origi-

Yes

nating in the perinatal period

1.184 (1.071,

< 0.001

1.309)

(P29)
Other conditions originating in

Yes

the perinatal period (P96)
Abnormalities

of

heart

2.412 (2.180,

< 0.001

2.668)
beat

Yes

(R00)

1.106 (1.024,

0.010

1.195)

Symptoms and signs concerning

Yes

food and fluid intake (R63)

1.630 (1.525,

< 0.001

1.742)
Yes

Surgical operation and other surgical procedures as the cause of

1.227 (1.091,
1.380)

abnormal reaction of the patient,
or of later complication, without
mention of misadventure at the
time of the procedure (Y83)

113

< 0.001

Encounter for observation and

Yes

evaluation of newborn for sus-

1.239 (1.126,

< 0.001

1.363)

pected diseases and conditions
ruled out (Z05)
Encounter

for

immunization

Yes

(Z23)

1.133 (1.029,

0.011

1.248)

Family history of certain disabili-

Yes

ties and chronic diseases (leading

0.641 (0.551,

< 0.001

0.745)

to disablement) (Z82)
Personal history of other diseases

Yes

and conditions (Z87)
Other

postprocedural

0.816 (0.734,

< 0.001

0.907)
states

Yes

(Z98)

0.698 (0.632,

< 0.001

0.770)

Pervasive developmental disor-

Yes

ders (F84)

0.577 (0.373,

0.013

0.893)

Sleep disorders (G47)

Yes

0.989 (0.842,

0.891

1.162)
Other functional intestinal disor-

Yes

ders (K59)

1.028 (0.895,

0.699

1.181)

Reaction to severe stress, and ad-

Yes

justment disorders (F43)

1.354 (1.157,

< 0.001

1.585)

Streptococcus, Staphylococcus,

Yes

and Enterococcus as the cause

1.031 (1.017,

< 0.001

1.046)

of diseases classified elsewhere
(B95)
Other anemias (D64)

Yes

0.965 (0.953,
0.978)
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< 0.001

Major depressive disorder, single

Yes

episode (F32)

< 0.001

0.976)

Pervasive developmental disor-

Yes

ders (F84)
Attention-deficit

0.946 (0.918,

1.063 (1.026,

< 0.001

1.102)
hyperactivity

Yes

disorders (F90)

0.934 (0.909,

< 0.001

0.960)

Sleep disorders (G47)

Yes

1.031 (1.014,

< 0.001

1.047)
Asthma (J45)

Yes

1.052 (1.036,

< 0.001

1.068)
Other functional intestinal disor-

Yes

ders (K59)

1.032 (1.020,

< 0.001

1.044)

Obstructive and reflux uropathy

Yes

(N13)

0.947 (0.921,

< 0.001

0.974)

Other disorders of urinary sys-

Yes

tem (N39)

1.034 (1.016,

< 0.001

1.052)

Convulsions, not elsewhere clas-

Yes

sified (R56)

0.956 (0.936,

< 0.001

0.977)

Outcome of delivery (Z37)

Yes

0.904 (0.873,

< 0.001

0.935)
Viral and other specified intesti-

Present

nal infections (A08)

1.096 (1.064,

< 0.001

1.128)

Viral agents as the cause of dis-

Present

eases classified elsewhere (B97)

1.044 (1.031,

< 0.001

1.058)

Sickle-cell disorders (D57)

Present

1.042 (1.023,
1.062)
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< 0.001

Neutropenia (D70)

Present

1.035 (1.023,

< 0.001

1.047)
Volume depletion (E86)

Present

1.048 (1.038,

< 0.001

1.058)
Other disorders of fluid, elec-

Present

trolyte and acid-base balance

0.980 (0.975,

< 0.001

0.986)

(E87)
Reaction to severe stress, and ad-

Present

justment disorders (F43)

1.032 (1.018,

< 0.001

1.047)

Conduct disorders (F91)

Present

1.066 (1.044,

< 0.001

1.089)
Epilepsy and recurrent seizures

Present

(G40)

1.026 (1.017,

< 0.001

1.035)

Essential (primary) hypertension

Present

(I10)

0.969 (0.959,

< 0.001

0.978)

Acute upper respiratory infec-

Present

tions of multiple and unspecified

1.047 (1.029,

< 0.001

1.065)

sites (J06)
Acute bronchiolitis (J21)

Present

1.086 (1.071,

< 0.001

1.101)
Asthma (J45)

Present

1.026 (1.017,

< 0.001

1.034)
Respiratory failure,

not else-

Present

where classified (J96)

0.977 (0.970,

< 0.001

0.983)

Other respiratory disorders (J98)

Present

0.986 (0.979,
0.994)
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< 0.001

Gastro-esophageal reflux disease

Present

(K21)

1.025 (1.016,

< 0.001

1.033)

Acute appendicitis (K35)

Present

1.076 (1.052,

< 0.001

1.100)
Other functional intestinal disor-

Present

ders (K59)

0.987 (0.980,

< 0.001

0.994)

Cellulitis and acute lymphangitis

Present

(L03)

1.065 (1.050,

< 0.001

1.080)

Scoliosis (M41)

Present

0.964 (0.951,

< 0.001

0.976)
Present

Disorders of newborn related to

1.124 (1.080,

< 0.001

1.169)

long gestation and high birth
weight (P08)
Neonatal jaundice from other

Present

and unspecified causes (P59)

1.049 (1.035,

< 0.001

1.063)

Transitory disorders of carbo-

Present

hydrate metabolism specific to

1.044 (1.022,

< 0.001

1.067)

newborn (P70)
Feeding problems of newborn

Present

(P92)

< 0.001

1.093)

Congenital malformations of car-

Present

diac septa (Q21)
Congenital

1.076 (1.059,

< 0.001

0.962)

malformations

of

Present

great arteries (Q25)
Abnormalities

0.955 (0.949,

of

0.965 (0.957,

< 0.001

0.974)
breathing

Present

(R06)

1.043 (1.036,
1.051)
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< 0.001

Other symptoms and signs in-

Present

volving the circulatory and res-

1.022 (1.013,

< 0.001

1.032)

piratory system (R09)
Abdominal

and

pelvic

pain

Present

(R10)

1.035 (1.023,

< 0.001

1.047)

Nausea and vomiting (R11)

Present

1.028 (1.019,

< 0.001

1.036)
Symptoms and signs involving

Present

emotional state (R45)

1.052 (1.035,

< 0.001

1.069)

Fever of other and unknown ori-

Present

gin (R50)

1.036 (1.028,

< 0.001

1.043)

Convulsions, not elsewhere clas-

Present

sified (R56)

1.053 (1.041,

< 0.001

1.065)
Present

Lack of expected normal physio-

1.023 (1.015,

< 0.001

1.032)

logical development in childhood
and adults (R62)
Place of occurrence of the exter-

Present

nal cause (Y92)

1.034 (1.023,

< 0.001

1.044)

Outcome of delivery (Z37)

Present

1.047 (1.019,

< 0.001

1.076)
Liveborn infants according to

Present

place of birth and type of deliv-

1.369 (1.342,

< 0.001

1.395)

ery (Z38)
Encounter for other aftercare and

Present

medical care (Z51)

1.048 (1.039,

< 0.001

1.057)

Personal risk factors, not else-

Present

where classified (Z91)

1.024 (1.012,
1.036)

118

< 0.001

Artificial opening status (Z93)

Present

1.024 (1.014,

< 0.001

1.033)

Table 4.8: Statistical interactions with age

Regression
Variable

p value
coefficient
Main effects of the interactions

Age

-0.042

Streptococcus, Staphylococcus, and
Enterococcus as the cause of diseases classified

0.342

elsewhere (B95)
Other anemias (D64)

0.371

Major depressive disorder, single episode (F32)

1.418

Pervasive developmental disorders (F84)
Attention-deficit hyperactivity disorders (F90)

-0.549
1.035

Sleep disorders (G47)

-0.011

Asthma (J45)

-1.437

Other functional intestinal disorders (K59)

< 0.001

0.027

Obstructive and reflux uropathy (N13)

-0.282

Other disorders of urinary system (N39)

-0.291

Convulsions, not elsewhere classified (R56)

-0.714

Outcome of delivery (Z37)

-0.528

Interaction terms with age
Streptococcus, Staphylococcus, and
Enterococcus as the cause of diseases classified

0.031

elsewhere (B95)
Other anemias (D64)

-0.035
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< 0.001

Major depressive disorder, single episode (F32)
Pervasive developmental disorders (F84)
Attention-deficit hyperactivity disorders (F90)

-0.055
0.061
-0.068

Sleep disorders (G47)

0.030

Asthma (J45)

0.051

Other functional intestinal disorders (K59)

0.031

Obstructive and reflux uropathy (N13)
Other disorders of urinary system (N39)

-0.054
0.033

Convulsions, not elsewhere classified (R56)

-0.045

Outcome of delivery (Z37)

-0.101
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Table 4.9: Statistical interactions with the number of medications

Regression
Variable

p value
coefficient
Main effects of the interactions

Number of medications

0.117

Viral and other specified intestinal infections
-1.117
(A08)
Viral agents as the cause of diseases classified
-0.549
elsewhere (B97)
Sickle-cell disorders (D57)

-1.054

Neutropenia (D70)

0.199

Volume depletion (E86)

-0.964
< 0.001

Other disorders of fluid, electrolyte and
0.592
acid-base balance (E87)
Reaction to severe stress, and adjustment
0.303
disorders (F43)
Conduct disorders (F91)

0.888

Epilepsy and recurrent seizures (G40)

-0.555

Essential (primary) hypertension (I10)

0.417

Acute upper respiratory infections of multiple
-0.797
and unspecified sites (J06)
Acute bronchiolitis (J21)

-1.273

Asthma (J45)

-1.437

Respiratory failure, not elsewhere classified
0.735
(J96)
Other respiratory disorders (J98)

0.348
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Gastro-esophageal reflux disease (K21)

-0.157

0.005

Acute appendicitis (K35)

-1.611

< 0.001

0.027

0.699

Cellulitis and acute lymphangitis (L03)

-1.295

< 0.001

Scoliosis (M41)

-0.034

0.787

-1.213

< 0.001

-0.039

0.421

-0.187

0.017

Other functional intestinal disorders (K59)

Disorders of newborn related to long gestation
and high birth weight (P08)
Neonatal jaundice from other and unspecified
causes (P59)
Transitory disorders of carbohydrate
metabolism specific to newborn (P70)

Feeding problems of newborn (P92)

0.422

Congenital malformations of cardiac septa
0.405
(Q21)
Congenital malformations of great arteries
0.57
(Q25)
< 0.001
Abnormalities of breathing (R06)

-0.676

Other symptoms and signs involving the
-0.322
circulatory and respiratory system (R09)
Abdominal and pelvic pain (R10)

-0.903

Nausea and vomiting (R11)

-0.519

Symptoms and signs involving emotional state
-0.387
(R45)
Fever of other and unknown origin (R50)

-0.773

Convulsions, not elsewhere classified (R56)

-0.714
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Lack of expected normal physiological
-0.124

0.037

development in childhood and adults (R62)
Place of occurrence of the external cause (Y92)

-0.764

Outcome of delivery (Z37)

-0.528
< 0.001

Liveborn infants according to place of birth
-1.577
and type of delivery (Z38)
Encounter for other aftercare and medical care
-0.31
(Z51)
Personal risk factors, not elsewhere classified
-0.242

0.002

-0.241

< 0.001

(Z91)
Artificial opening status (Z93)

Interaction terms with Number of medications
Viral and other specified intestinal infections
0.091
(A08)
Viral agents as the cause of diseases classified
0.043
elsewhere (B97)
Sickle-cell disorders (D57)

0.041

Neutropenia (D70)

0.034

Volume depletion (E86)

0.047

Other disorders of fluid, electrolyte and
-0.02
acid-base balance (E87)
Reaction to severe stress, and adjustment
0.032
disorders (F43)
Conduct disorders (F91)

0.064

Epilepsy and recurrent seizures (G40)

0.026

Essential (primary) hypertension (I10)

-0.032
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Acute upper respiratory infections of multiple
0.046
and unspecified sites (J06)
Acute bronchiolitis (J21)

0.082

Asthma (J45)

0.025

Respiratory failure, not elsewhere classified
-0.024
(J96)
Other respiratory disorders (J98)

-0.014

Gastro-esophageal reflux disease (K21)

0.024

Acute appendicitis (K35)

0.073

Other functional intestinal disorders (K59)
Cellulitis and acute lymphangitis (L03)
Scoliosis (M41)

-0.013
0.063
-0.037

Disorders of newborn related to long gestation
0.117
and high birth weight (P08)
Neonatal jaundice from other and unspecified
0.048
causes (P59)
Transitory disorders of carbohydrate
0.043
metabolism specific to newborn (P70)
Feeding problems of newborn (P92)

0.073

Congenital malformations of cardiac septa
-0.046
(Q21)
Congenital malformations of great arteries
-0.036
(Q25)
Abnormalities of breathing (R06)

0.042

Other symptoms and signs involving the
0.022
circulatory and respiratory system (R09)
Abdominal and pelvic pain (R10)

0.034

Nausea and vomiting (R11)

0.027
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Symptoms and signs involving emotional state
0.051
(R45)
Fever of other and unknown origin (R50)

0.035

Convulsions, not elsewhere classified (R56)

0.052

Lack of expected normal physiological
0.023
development in childhood and adults (R62)
Place of occurrence of the external cause (Y92)

0.033

Outcome of delivery (Z37)

0.046

Liveborn infants according to place of birth
0.314
and type of delivery (Z38)
Encounter for other aftercare and medical care
0.047
(Z51)
Personal risk factors, not elsewhere classified
0.023
(Z91)
Artificial opening status (Z93)

0.023
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